

# CURRICULUM VITAE

## Curriculum Vitae

**Michael R. Gold, M.D., Ph.D.**

Office Address: Division of Cardiology  
Medical University of South Carolina Phone: (843)876-4760  
25 Courtenay Drive, ART 7031 Fax: (843)876-4990  
MSC 592  
Charleston, SC 29425-5290

Citizenship: USA

### **Education**

SUNY at Stony Brook	1973-5	BS	1975	Biology/Mathematics
University of Virginia	1975-9	PhD	1979	Physiology
University of Colorado	1981-5	MD	1985	Medicine
Internship (Medical)	Massachusetts General Hospital		1985-6	
Residency	Massachusetts General Hospital		1986-8	
Postdoctoral Fellowship	University of Colorado		1979-81	
Clinical Fellowship	Massachusetts General Hospital		1988-91	

### **Board Certifications**

Diplomate, National Board of Medical Examiners	1986
American Board of Internal Medicine	1988
American Board of Internal Medicine, Cardiovascular Subspecialty	1991
American Board of Internal Medicine, Clinical Cardiac Electrophysiology	1992

### **Medical Licensures**

State of Massachusetts	1987 (inactive)
State of Maryland	1991 (inactive)
State of South Carolina	2002

### **Faculty Appointments**

1991-1997	Assistant Professor	University of Maryland	Medicine
1998-2000	Associate Professor	University of Maryland	Medicine
2001-2002	Professor	University of Maryland	Medicine
1991-2000	Assistant Professor	University of Maryland	Physiology
2001-2002	Associate Professor	University of Maryland	Physiology
2002-	Professor	Medical University of South Carolina	Medicine
2002-	Michael E. Assey Chair	Medical University of South Carolina	Medicine

### **Administrative Appointments**

1991- 2002	Director of Cardiac Electrophysiology	University of Maryland
1991- 2002	Director Cardiac Electrophysiology Fellowship	University of Maryland

2002-	Director, Division of Cardiology	Medical University of South Carolina
2002-	Medical Director, Progressive Care Unit	Medical University of South Carolina
2002- 2007	Medical Director, Heart and Vascular Center	Medical University of South Carolina
2007-	Associate Dean, Interdisciplinary Clinical Prog.	Medical University of South Carolina

### **Hospital Appointments**

1991- 2002	Inactive	University of Maryland
1991- 2002	Inactive	Baltimore VA Medical Center
2002	Active	Medical University of South Carolina
2002	Active	Ralph H. Johnson VA Medical Center

### **Professional Society Memberships**

Society for Neuroscience	1977-1982
American Heart Association	1988-present
American College of Cardiology	1989-present
American College of Chest Physicians	1989-1992
NASPE	1991-present
American Federation for Clinical Research	1992-present
Fellow, American College of Cardiology	1992-present
Association of Professors of Cardiology	2002-present
Charleston County Medical Society	2003-present
American College of Cardiology (SC Chapter)	2003-present
Fellow, Heart Rhythm Society	2006-present

### **Editorial Positions**

Journal of Cardiovascular Electrophysiology	1999-present
American Journal of Cardiology	2002-present
Current Cardiology Reports	2003-present
Heart Rhythm	2003-present
PACE	2004-present
Journal of Cardiothoracic Renal Research	2005-present

### **Extramural Grant Support**

#### **NIH Sponsored**

Principal Investigator	National Institutes of Health, "SCD-HeFT Sub-Study Protocol: T-Wave Alternans:". 1 R01 HL 55766-01A1 (5%)
Local Principal Investigator 9/1/92 - 8/31/97	National Institutes of Health, "MUSTT" (The Use of Electrophysiologic Studies to Guide Therapy for Non-Sustained Ventricular Tachycardia). Total Costs:\$120,638 (Direct \$120,638)
Local Principal Investigator	National Institutes of Health, "SCD-HeFT" (Sudden Cardiac Death in Heart Failure Trial). Total Costs: \$89,000 (Direct \$80,833;

5/1/95 - 7/31/95	Indirect \$8,167) Pilot Study
Local Principal Investigator 6/15/95 - 8/31/98	National Institutes of Health, "AVID"(Antiarrhythmics vs Implantable Cardiac Defibrillator Clinical Trial). Total Costs: \$64,800 (Direct \$54,000; Indirect \$10,800)
Local Principal Investigator 2/20/96 - 4/30/01	National Institutes of Health, "AFFIRM" (Atrial Fibrillation Follow-Up Investigation of Rhythm Management). Total Costs: \$22,000 (Direct \$18,000; Indirect \$4,000)
Local Principal Investigator 8/1/97 - 7/31/00	National Institutes of Health, ScD-HEFT (Sudden Cardiac Death in Heart Failure Trial). Total Costs: \$265,000 (Direct \$220,834; Indirect \$44,166)
<u>American Heart Sponsored</u>	
Principal Investigator 7/1/92 - 6/30/94	American Heart Association, Grant-In-Aid, "Physiologic Modulation of Cardiac Sodium and Gap Junction Conductance". Total Costs: \$44,000 (Direct \$40,000; Indirect \$4,000)
<u>Training Grant</u>	
	NASPE Fellowship in Cardiac Electrophysiology (\$50,000 annually)
<u>Industry Sponsored</u>	
Principal Investigator 10/1/90 - 10/30/92	Telectronics Pacing Systems, "Clinical Evaluation of the Guardian 4203 System". Total Costs:\$11,425 (Direct \$9,521; Indirect \$1,904)
Principal Investigator 11/17/92 - 1/15/95	Telectronics Pacing Systems, "Clinical Evaluation of the Guardian 4204 System". Total Costs:\$11,121 (Direct \$9,268; Indirect \$1,853)
Principal Investigator 11/2/93 - 11/1/95	Bristol-Meyers Squibb, "Efficacy and Safety of d-Sotalol Versus Placebo in the Maintenance of Sinus Rhythm Following Pharmacologic or Electrical Cardioversion in Subjects with Sustained Atrial Fibrillation or Atrial Flutter". Total Costs:\$13,678 (Direct \$ 11,398; Indirect \$2,280)
Principal Investigator 2/1/94 - 12/31/95	Bristol-Meyers Squibb, "Comparison of Intravenous D-Sotalol and Placebo in the Conversion of Atrial Fibrillation or Flutter to Sinus Rhythm". Total Costs:\$14,524 (Direct \$12,103 ; Indirect \$2,421)
Principal Investigator 2/1/94 - 7/31/95	Bristol-Meyers Squibb, "Comparison of the Safety and Efficacy of d-Sotalol and d,L-Sotalol in Patients with Life-Threatening Ventricular Tachycardia (VT) and Ventricular Fibrillation: A Randomized, Double-Blind, Multicenter Study". Total Costs: \$3,000 (Direct \$2,500; Indirect \$500)
Principal Investigator	Bristol-Meyers Squibb, "Dose Ranging Study of Oral d-Sotalol in

8/15/94 - 8/14/95	Patients with Life-Threatening Ventricular Arrhythmias". Total Costs: \$332,357 (Direct \$276,964; Indirect \$55,393)
Principal Investigator 8/15/94 - 8/14/95	Berlex, "Placebo Controlled Evaluation of the Efficacy and Safety of Oral Sotalol in Patients with Life-Threatening Ventricular Arrhythmias and Implanted Cardioverter Defibrillators".
Principal Investigator 1/17/94 - 1/16/95	Medtronic, "The Clinical Investigation of the Medtronic Model 7202D Jewel Cardioverter/Defibrillator System with Transvene and Epicardial Leads". Total Costs: \$8,500 (Direct \$7,083; Indirect \$1,417)
Principal Investigator 10/1/93 - 9/30/94	Medtronic, "The Clinical Investigation of the Model 7217B PCD Multi-Programmable Tachyarrhythmia Control System with Epicardial Leads". Total Costs: \$2,000 (Direct \$1,667; Indirect \$333)
Principal Investigator 7/1/93 - 6/30/95	Boston-Scientific, "Clinical Trial of the Polaris LERF Ablation System for RF Catheter Ablation of Supraventricular Arrhythmias". Total Costs: \$8,986 (Direct \$7,488 ; Indirect \$1,498)
Principal Investigator 6/1/93 - 5/31/94	Merck & Co., "An Open-Label Study to Evaluate the Safety and Electrophysiologic Effects of MK-499 Administered Orally Once Daily (QD) or Twice Daily (BID) to Patients with Life-Threatening Ventricular Arrhythmias". Total Costs: \$90,340 (Direct \$75,283; Indirect \$15,057)
Principal Investigator 6/15/94 - 6/14/95	Merck & Co., "A Double-Blind, Randomized, Parallel, Sotalol-Controlled, Dose Confirmation Study to Investigate the Safety and Electrophysiologic Effects of MK-499 in Patients with Sustained Ventricular Tachyarrhythmias". Total Costs: \$343,576 (Direct \$286,313 ; Indirect \$57,263)
Principal Investigator 5/1/94 - 12/31/95	Siemens, "Clinical Investigation of Siemens Pacesetter Model 1242T". Total Costs: \$6,000 (Direct \$5,000; Indirect \$1,000)
Principal Investigator 1/17/94 - 6/30/96	Medtronic, "Clinical Investigation of Model 6937 SVC Lead with the Jewel System". Total Costs: \$5,000 (Direct \$4,167; Indirect \$833)
Principal Investigator 6/24/94 - 12/31/96	Medtronic, "Investigational Plan Atrial Lead Study". Total Costs: \$6,000 (Direct \$5,000; Indirect \$1,000)
Principal Investigator 3/6/95 - 3/5/96	Pfizer, Inc., "A Randomized, Double-Blind, Parallel, Placebo-Controlled Evaluation of Orally Administered Dofetilide in Patients with Symptomatic Paroxysmal Atrial Fibrillation/Flutter (pAF, pAFL) or Paroxysmal Supraventricular Tachycardia

	(pSVT)". Total Costs: \$83,400 (Direct \$69,500; Indirect \$13,900)
Principal Investigator 6/1/95 - 6/30/96	Cardiac Pacemakers, Inc., "Pectoral Clinical Investigation of the Ventak PRx III Model 1721 HC Hot Can Pulse Generator". Total Costs: \$7,500 (Direct \$6,250; Indirect \$1,250)
Principal Investigator 6/1/95 - 6/1/96	Cardiac Pacemakers, Inc., "Intracardiac Recordings of Ventricular Tachycardia (VT) and Atrial Fibrillation (AF) Signals During Implant of Endotak Leads". Total Costs: \$30,000 (Direct \$25,000; Indirect \$5,000)
Principal Investigator 5/12/95 - 5/11/98	Intermedics, "Investigational Plan for the Clinical Evaluation of the 430-10 and 432-04 Thinline Pacing Leads". Total Costs: \$6,000 (Direct \$5,000; Indirect \$1,000)
Principal Investigator 1/17/96 - 1/16/97	New England Deaconess Hospital, "TOVA" (Triggers of Ventricular Arrhythmias Pilot Study). Total Costs: \$1,500 (Direct \$1,250; Indirect \$250)
Principal Investigator 3/15/91 - 12/31/92	Sterling, "The Electrophysiologic Effects of Oral Ipazilide in Subjects with Sustained Ventricular Tachyarrhythmias". Total Costs: \$265,076 (Direct \$220,897; Indirect \$44,179)
Principal Investigator 12/2/91 - 10/15/92	Searle, "Phase II Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Different Doses of Bidisomide Administered Orally to Prevent Ventricular Ectopy in Patients with Implanted Cardioverter/Defibrillator". Total Costs: \$3,975 (Direct \$3,313; Indirect \$662)
Principal Investigator 12/1/92 - 11/30/93	Merck & Co., "Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Investigate the Safety, Tolerability and Electrographic Effects of Rise in Single Oral Doses of L-706,000 in Patients with Coronary Artery Disease". Total Costs: \$4,672 (Direct \$3,893; Indirect \$779)
Principal Investigator 7/89 - 6/91	Warner-Lambert Corporation, "Procainamide on Cardiac Arrhythmias Post Coronary Bypass Graft Surgery". Total Costs: \$89,156
Principal Investigator 6/1/95 - 12/31/97	Cardiac Pacemakers, Inc., "Effect of Pulse Width and Electrograms on Defibrillation Function". Total Costs: \$60,000 (Direct \$50,000; Indirect \$10,000)
Principal Investigator 3/1/96 - 2/28/97	Medtronic, "Clinical Investigation of the Medtronic Model 7218SP1 Arrhythmia Management Device". Total Costs: \$10,000 (Direct \$8,333; Indirect \$1,667)

Principal Investigator 3/15/97 - 3/14/99	Medtronic, "Shock Polarity on Defibrillation Thresholds with Active Can Lead". Total Costs: \$15,000 (Direct \$12,500; Indirect \$2,500)
Principal Investigator 11/6/96 - 5/5/98	Proctor & Gamble Pharmaceuticals, "Evaluation of the Efficacy and Safety of Oral Azimilide Dihydrochloride in Patients with an ICD". Total Costs: \$139,000 (Direct \$115,833; Indirect \$23,167)
Principal Investigator 8/1/97 - 7/31/98	Cardiac Pacemakers, Inc., "Cardioversion and Discrimination of A-Fib with an Active Can ICD Lead System". Total Costs: \$30,000 (Direct \$25,000; Indirect \$5,000)
Principal Investigator 2/1/97 - 9/30/98	Cardiac Pacemakers, Inc., "Clinical Investigation of SELUTE Picotip and SELUTE Picotip Atrial J Leads". Total Costs: \$10,000 (Direct \$8,333; Indirect \$1,667)
Principal Investigator 9/1/96 - 9/30/97	Cardiac Pacemakers, Inc., "Biventricular Pacing in Congestive Heart Failure". Total Costs: \$6,000 (Direct \$5,000; Indirect \$1,000)
Principal Investigator 10/1/97 - 12/31/98	Cardiac Pacemakers, Inc., "Acute Clinical Test of Left Ventricular Access Leads". Total Costs: \$36,000 (Direct \$30,000; Indirect \$6,000)
Principal Investigator 10/18/96 - 7/30/98	Mt. Sinai Medical Center, "DDD Versus DDDR Pacing: A Quality of Life Study". Total Costs: \$20,000 (Direct \$16,667; Indirect \$3,333)
Principal Investigator 10/1/97 - 10/1/98	Cardiac Pacemakers, Inc., "Effect of an Active Abdominal Pulse Generator on Defibrillation Thresholds". Total Costs: \$20,000 (Direct \$16,667; Indirect \$3,333)
Principal Investigator 11/1/97 - 10/31/98	Cardiac Pacemakers, Inc., "Intracardiac Electrogram Morphology During Normal Sinus Rhythm". Total Costs: \$7,500 (Direct \$6,250; Indirect \$1,250)
Principal Investigator 5/21/97 - 5/31/00	Cardiac Pacemakers, Inc., "Low Energy Safety Study (LESS)". Total Costs: \$93,000 (Direct \$77,500; Indirect \$15,500)
Principal Investigator 10/10/97 - 10/9/98	Irvine Biomedical, Inc., "Therapy Ablation Catheter System". Total Costs: \$24,000 (Direct \$20,000; Indirect \$4,000)
Principal Investigator 9/1/96 - 10/31/98	Cambridge Heart, "Effectiveness of T-Wave Alternans to SAECG". Total Costs: \$185,175 (Direct \$149,050; Indirect \$36,125)
Principal Investigator 9/1/96 - 1/31/97	Cambridge Heart, "Alternans Cardiac Electrical Stability Post MI". Total Costs: \$50,000 (Direct \$41,667; Indirect \$8,333)
Principal Investigator	Cardiac Pacemakers, Inc., "Chronic Defibrillation Function with a

2/18/97 - 2/17/98	Transvenous Lead System”/”Effect of Shock Polarity of DFT with Active Can Lead Systems”. Total Costs: \$20,000 (Direct \$16,667; Indirect \$3,333)
Principal Investigator 7/1/97 - 7/31/98	Pacesetter, Inc., “Acute Hemodynamic Effects of Biventricular Pacing in Congestive Heart Failure”. Total Costs: \$44,634 (Direct \$37,195; Indirect \$7,439)
Principal Investigator 11/1/97 - 10/31/98	Cardiac Pacemakers, Inc., “Endotak Endurance RX Defibrillation Lead System”. Total Costs: \$12,000 (Direct \$10,000; Indirect \$2,000)
Principal Investigator 2/1/98 - 1/31/99	Cardiac Pacemakers, Inc., “Ventak CHF Biventricular Pacing Study”. Total Costs: \$64,000 (Direct \$53,333; Indirect \$10,667)
Principal Investigator 12/1/97 - 12/31/98	Medtronic, “Electrode Position on Ventricular DFT”. Total Costs: \$20,000 (Direct \$16,667; Indirect \$3,333)
Principal Investigator 2/1/00-2/1/01	Medtronic, “The Effect of Multimodal Therapy to Maintain Sinus Rhythm in Patients with Congestive Heart Failure and Persistent Atrial Fibrillation”. Total Costs: \$397,440 (Direct \$317,880; Indirect \$79,560)
Principal Investigator 5/1/99-5/1/01	EPMed Systems, “A Clinical Trial of the Alert System”. Total \$29,652 (Direct \$23,652, Indirect \$6,000)
Principal Investigator 2002-2003	UDAK HR# 10396 Medtronic Model 2960 Research Defibrillation Feasibility Study Sponsor – Medtronic Grant Amount \$26,200 <b>\$12653.13</b>
<b>Principal Investigator</b> 2002-2003	UDAK 83850 HR# 10397 A Randomized, Double Blind, Placebo Controlled Study of Intravenous CVT-150 in Patients with PSVT undergoing an Electrophysiology Study Sponsor - CV Therapeutics Grant Amount \$30,000 \$ 8300.49
Principal Investigator 2002-2003	UDAK HR# 10398 Ventak Prizm AVR US Investigational Plan Study Sponsor – Guidant Grant Amount \$25,251 <b>\$19006.33</b>
Principal Investigator 2002-2004	<b>HR# 10478 Dose Response Curve for Transthoracic Cardioversion of Atrial Fibrillation with Biphasic Shocks</b>
<b>Principal Investigator</b> 2002-2005	UDAK 84073 HR# 10567 St. Jude Medical Epic HF Implantable Cardioverter Defibrillator System RHYTHM ICD Study , Study Sponsor – St. Jude Medical Grant Amount \$151,750 <b>\$146295.73</b>
Principal Investigator 2002-2007	UDAK 84026 HR# 10601 Study for Atrial Fibrillation Reduction Investigational Plan (SAFARI) Study Sponsor – Vitatron Grant

Amount \$43,275 ~~\$48117.17~~

- Principal Investigator  
2003 - ongoing      [HR# 10868 Recurrent Atrial Fibrillation: Biomarkers of Matrix Remodeling](#)
- Principal Investigator  
2003-2007      UDAK 84396 HR# 10881 Device Evaluation of CONTAK RENEWAL 2 and EASYTRAK 2 Assessment of Safety and Effectiveness in Heart Failure Sponsor – Guidant Grant Amount \$181,650 ~~\$170700.00~~
- Principal Investigator  
2003-2005      UDAK 84451 HR# 10947 CRT Optimization Algorithm Validation Study Study Sponsor – Guidant Grant Amount \$80,800 ~~\$84730.41~~
- Principal Investigator  
2003-2006      UDAK 84658 HR# 11000 Multiple Atrial Therapies in Congestive Heart Failure Treatment (MATCH) Study Sponsor – Medtronic Grant Amount \$116,500 ~~\$29900.00~~
- Principal Investigator  
2004-2008      UDAK 84802 HR# 11210 CONTAK Renewal 3 AVT Protocol Study Sponsor – Guidant Grant Amount \$62,250 ~~\$38323.93~~
- Principal Investigator  
2004-ongoing      UDAK 85139 HR# 11452 Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction (REVERSE) Study Sponsor – Medtronic Grant Amount \$238,590 \$162334.64
- Principal Investigator  
2004-ongoing      UDAK 85152 HR# 11493 St. Jude Medical Device System Post-Approval Surveillance Study Sponsor – St. Jude Medical Grant Amount \$12,500 ~~\$13000.00~~
- Principal Investigator**  
2006      UDAK85209 HR# 15057 GDT1000 Sensing Acute Study 2004-Sponsor – Guidant Grant Amount \$22,500 ~~\$14500.00~~
- Principal Investigator**  
2004 – ongoing      UDAK 85318 HR# 15140 Asymptomatic AF and Stroke Evaluation in Pacemaker Patients and the AF Reduction Atrial Pacing Trial (ASSERT) Study Sponsor – St. Jude Medical Grant Amount \$31,500 \$28060.00
- Principal Investigator**  
2005 – ongoing      UDAK 85328 HR# 15216 Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy (MADIT CRT) Study Sponsor – Guidant Grant Amount \$118,215  
\$44031.00
- Principal Investigator  
2005-2007      UDAK 85346 HR# 15244 Optimal SVC Coil Usage in ICD Patients Study Sponsor – St. Jude Medical Grant Amount \$37,000  
~~\$37000.00~~
- Principal Investigator**  
2005-2007      UDAK 85546 HR# 15614 GDT2000 Acute RV Auto Threshold Study Study Sponsor – Guidant Grant Amount \$32,500 ~~\$32500.00~~

- Principal Investigator**  
2005-2008 UDAK 85898 HR# 15708 A Comparison of Right Ventricular Apical and Outflow Tract Lead Positions on Defibrillation Thresholds Study Sponsor – Medtronic Grant Amount \$39,950 \$39950.00
- Principal Investigator**  
2005-2006 [HR# 15742 The Effect of Dofetilide on Defibrillation Thresholds](#)
- Principal Investigator**  
2005-ongoing UDAK 85637 HR# 15789 First Arrhythmia Collection of Transvenous and Simultaneous Subcutaneous Implantable Defibrillator (S-ICD) Data (FACTS S-ICD) Study Study Sponsor – Cameron Health Inc Grant Amount \$43,000 \$45000.00
- Principal Investigator**  
2005-2007 UDAK 85703 HR# 15860 Atrial Fibrillation Suppression Pacing in Cardiac Resynchronization Therapy Device (AF Suppression/CRT-D Study) Study Sponsor – St. Jude Medical Grant Amount \$31,000 \$6272.00
- Principal Investigator**  
2005 - 2008 UDAK 85362 HR# 15940 Resynchronization Therapy in Normal QRS (RethinQ) Study Study Sponsor – St. Jude Medical Grant Amount \$68,700 \$108081.00
- Principal Investigator**  
2006 - 2008 UDAK 85953 HR# 16291 Guidant EASYTRAK 3 Downsize Lead 4591/4592/4593 Clinical Study, Study Sponsor – Guidant Grant Amount \$53,500 \$15650.00
- Principal Investigator**  
ongoing UDAK 86595 HR# 17454 The REPLACE Registry Study 2007 – Sponsor – Biotronik, Inc. Grant Amount \$78,000 \$26218.75
- Principal Investigator**  
2007-ongoing UDAK 86597 HR# 17480 Prospective, Multi-center Study of the Ability of the PD2i Cardiac Analyzer to Predict Risk of Ventricular Tachyarrhythmic Events Such as Sudden Cardiac Death (SCD), Ventricular Fibrillation (VF) pr Ventricular Tachycardia (VT) in High Risk Patients Study Sponsor – Vicor Technologies, Inc. Grant Amount \$30,000 \$2500.00
- Principal Investigator**  
2007 – ongoing UDAK 86775 HR# 17580 Rate-Dependent A-V Delay by Exercise (RAVE) Study Sponsor – Boston Scientific Grant Amount unknown ptd \$26125.00
- Principal Investigator**  
2008 – ongoing UDAK 86923 HR# 18102 Safety of Sports for Patients with Implantable Cardioverter-Defibrillators: A Multicenter Registry Study Sponsor – Co sponsored by Boston Scientific, Inc, Medtronic and St. Jude Medical Grant Amount unknown ptd \$2500.00
- Principal Investigator**  
2008 – ongoing UDAK 87140 HR# 18078 Effect of Cardiac Resynchronization Therapy (CRT) on the Defibrillation Threshold (DFT) Estimates

Study Sponsor – St. Jude Medical Grant Amount \$28,760  
\$6964.00

**Principal Investigator** UDAK ??? HR# 18516 AF-CRT Study: The Effect of  
2008 – ongoing Biventricular Pacing on the Incidence of Atrial Fibrillation Study  
Sponsor – AF Research Inc

### **Awards and Honors**

Traveling Fellow, National Research, Council Award to Sydney, Australia	1983
Lange Award for Academic Performance	1983
Richard Whitehead Award in Pharmacology	1983
Academic Achievement Award	1984
Alpha Omega Alpha	1984
Willard Smith Scholarship for Promise in Medicine	1984
Adler Scholarship for Research	1985
Lange Award for Academic Performance	1985
Gold Headed Cane Award	1985
Joseph and Regina Glaser Research Prize	1985
Samuel J. Katcef Fellow, American Heart Association	1992

### **Academic Committee Activity**

#### University

Member, MD/PhD Committee, University of Maryland	1992-2002
Member, Procedural Workgroup, University of Maryland	1997-2002
Member, Post Graduate Education Committee, University of Maryland	1997-2002
Member, Cardiac Steering Committee, University of Maryland	2000-2002
Member, Clinical Council, Medical University of South Carolina	2002-
Member, Physician Clinical Directors, Medical University of South Carolina	2004-

### **Teaching Responsibilities**

Lectures to Graduate Nursing Students University of Virginia	1978
Lectures in Internal Medicine to Harvard medical students	1987
Cardiology instruction to Harvard medical students	1988-1989
ECG Conference for cardiology fellows	1991-2002
Lectures in Medical School Physiology and Pharmacology	1991-2002

### **Major Clinical Research Interests**

Optimization of Defibrillation Function  
Risk Stratification of Sudden Cardiac Death  
Pacing for Congestive Heart Failure  
Ablation of Cardiac Arrhythmias

### **Invited Lectures and Presentations (selected)**

2000

George Washington University, Washington, DC-Grand Rounds  
University of Washington, Seattle WA, Grand Rounds  
Vitatron, Mt. Crested Butte, CO-Physician Educational Program. "Practical Approaches to Arrhythmia Management"  
Easton Hospital, Easton, PA-Grand Rounds  
Northwest Electrophysiology Society, Bend, OR. "Pacing for CHF"  
Memorial Hospital, Colorado Springs-Grand Rounds  
Colorado EP Society, Castle Rock, CO  
Cedars Medical Center, Miami, FL-Cardiology Symposium. "Sudden Cardiac Death Risk Stratification and Update on Atrial Fibrillation"  
Guidant Corporation, Bay Area Cardiology Seminar, Orlando, FL  
Metro General, Cleveland, OH-Grand Rounds  
Guidant Corporation, Washington, DC-Physicians Arrhythmia Seminar. "Pacing for Heart Failure"  
Mercy Medical Center, Baltimore, MD-Grand Rounds  
Colorado Cardiac Alliance, Colorado Springs, CO. "What's New in Arrhythmia Management"  
Wolfheze 2000 Dutch Annual Cardiac Arrhythmia Meeting  
American Heart Association, Syracuse, NY-Annual Heart Teaching Day for Physicians

#### 2001

Encino Tarzana Regional Medical Center, Tarzana, CA - Seventh Annual Cardiology Symposium  
Oklahoma ACC Chapter, Tulsa, OK. "Use of T-Wave Alternans for Predicting Sudden Cardiac Death"  
Guidant Corporation, Beaver Creek, CO. "Optimization of Defibrillator Functions"  
Medtronic, Snowbird, UT - EP at Snowbird  
University of Louisville, Louisville, KY- 3<sup>rd</sup> International Symposium on Advances in Interventional Electrophysiology  
University of Maryland, Baltimore, MD - Update in Internal Medicine. "Update on the Management of Atrial Fibrillation"  
Europace 2001, Copenhagen, Denmark - The European Working Groups on Cardiac Pacing and Arrhythmias  
University of Korea, Seoul, Korea - 6<sup>th</sup> Annual University of Korea Symposium on Arrhythmias. "Device Therapy for Atrial Fibrillation"  
International Academy of Cardiology 2<sup>nd</sup> International Congress on Heart Disease - New Trends in Research, Diagnosis and Treatment, Washington, DC. "T-Wave Alternans for Arrhythmia Risk Stratification"  
Duke University, Cardiology Grand Rounds  
Beth Israel Hospital, New York, Cardiology Grand Rounds

#### 2002

7<sup>th</sup> International Boston Atrial Fibrillation Symposium-Mechanisms and New Directions in Therapy, Boston, Massachusetts  
Tommy LaSorda Heart Institute Program, Vail, CO-"Diagnosis and Treatment of Common Cardiovascular Disorders: State-of-the-Art"  
University of Pennsylvania, Philadelphia, PA, Cardiology Grand Rounds  
Grossmont Hospital-San Diego, CA, Cardiology Conference-"Resynchronization Therapy for Heart Failure"

Michael R Gold, M.D., Ph.D.

Curriculum Vitae

Page 12

University of California, San Francisco, CA, Heart Disease in Women  
Carolina Family Care, Charleston, SC-“Prevention of Sudden Cardiac Death”  
Easton Memorial Hospital, Easton, PA, Cardiology Grand Rounds  
Alvarado Hospital Medical Center, San Diego, CA-“Cardiac Resynchronization Therapy for  
Congestive Heart Failure”  
MUSC CME Conference, Charleston, SC-“Advances in Cardiology Care”  
University Hospitals of Cleveland, Cleveland, OH, Update on Nonpharmacological Management  
of Atrial Fibrillation, Heart Failure and Prevention of Sudden Cardiac Death-“Implantable  
Devices for the Treatment of Atrial Fibrillation”  
University of Pennsylvania Medical Center, Philadelphia, PA, 10<sup>th</sup> Annual State-of-the-Art  
Arrhythmia Symposium  
Arrhythmia Management Conference, Vail, CO-“Epidemiology and Clinical Predictions of  
Cardiac Arrest”  
Shands University Hospital, Jacksonville, FL, Cardiology Grand Rounds

### 2003

EP Society, San Diego, CA  
UCSD Medical Center, San Diego, CA-“Cardiac Resynchronization Therapy for Heart Failure:  
Selecting and Optimizing Patients”  
MUSC Women’s Club-“Women & Heart Disease”  
SCAI Annual Cardiovascular Conference, Hawaii  
XII World Congress on Cardiac Pacing & Electrophysiology, Hong Kong  
Clinical Electrophysiology in Europe-7<sup>th</sup> Interlaken Symposium, Switzerland-“Clinical  
Electrophysiology in Europe: From Science to Guidelines to Practice?”  
Charleston Symposium on Interventional Pediatric Electrophysiology, Kiawah Island, SC-  
“Cardiac Resynchronization Therapy-State of the Art”  
27<sup>th</sup> Update in Cardiology for the Primary Physician, Charleston, SC  
Southern Colorado Heart Institute, EP in Aspen Conf, Aspen, CO

### 2004

SCAI Annual Cardiovascular Conference, Hawaii  
“Managing Arrhythmias & Heart Failure”, San Diego, CA  
Cardiostim, Nice-France  
Southern Colorado Heart Institute, EP in Aspen Conf, Aspen, CO  
“New Arrhythmia Technologies Retreat”, Bloomingdale, IL  
28<sup>th</sup> Update in Cardiology for the Primary Physician, Charleston, SC

### 2005

SCAI Annual Cardiovascular Conference, Hawaii  
Mt. Sinai, Miami Beach, FL, Cardiology Grand Rounds  
European CHF Mtg., Lisbon, Portugal  
Orange County EP Society  
Europace, Prague, Czech Republic  
Cardiovascular Research Institute at Washington Hospital Center, “Cardiac Resynchronization  
Therapy: A Decade of Progress”  
29<sup>th</sup> Update in Cardiology for the Primary Physician, Charleston, SC

### 2006

Michael R Gold, M.D., Ph.D.

Curriculum Vitae

Page 13

Boston Atrial Fibrillation Symposium, Massachusetts General Hospital

37th Annual Cardiovascular Conference, Snowmass, CO

Heart Center Grand Rounds @ Cleveland Clinic, "Cardiac Resynchronization Therapy: A  
Decade of Progress"

SCAI Annual Cardiovascular Conference, Hawaii

Cornell Hospital, Grand Rounds

Baylor College, Grand Rounds

NCLVD, "Managing Risk for Sudden Cardiac Death", Miami Beach, FL

Cardiology Fellows Fall Symposium, Boston, MA

Heart Failure Society, Seattle, WA

Controversies and Conundrums in Cardiovascular Medicine 2006 Conference, University of New

Mexico Health Sciences Center School of Medicine, Santa Fe, NM

International Symposium on Progress in Clinical Pacing, Rome, Italy

2007

38<sup>th</sup> Annual Cardiovascular Conference, Snowmass, CO  
CardioRhythm 2007, Hong Kong  
SCAI Annual Cardiovascular Conference, Hawaii  
UCLA Medical Center, Grand Rounds  
University of South Florida, Cardiology Grand Rounds  
Europace 2007, Lisbon, Portugal

2008

39<sup>th</sup> Annual Cardiovascular Conference, Snowmass, CO  
SCAI Annual Cardiovascular Conference, Hawaii  
Cardiology Grand Rounds, Hamilton Gen. Hospital, McMaster Clinic, Hamilton, Ontario Canada  
Grand Rounds, Brown University, Providence RI  
Grand Rounds, Boston University, Boston, MA  
Heart Rhythm Society, San Francisco, CA  
World Congress of Cardiology, Buenos Aires, Argentina  
Cardiostim, Nice, France  
Grand Rounds, University of Texas, San Antonio, TX  
Grand Rounds, University of Colorado, Denver, CO  
Ventricular Symposium, University of Miami, Miami, FL  
Cardiology & Medical Grand Rounds, George Washington University, Washington, DC

2009

18th Annual Cardiovascular Conference @ Beaver Creek, CO  
CardioRhythm 2009, Hong Kong  
Grand Rounds, St. Luke's Hospital, Houston, TX

**Extramural Professional Activities**

Member, AHA Maryland Affiliate, Peer Review Committee	1992-1995
Member, MUSTT, Recruitment Committee	1994-1999
Member, Merck, Arrhythmia Event Committee	1995-1996
Member, AVID, Device Committee	1995-1999
Member, AFFIRM, Publications Committee	1995-
Abstract Reviewer-AHA/NASPE/ACC Meetings	1996-
Member, SCD-HeFT Operations and Substudy Committees	1997-
Member, Procter & Gamble, Arrhythmia Board	1998-2001
Member, NASPE Government Relations Committee	1999-2002
Member, NASPE CME Committee	2000-2002
Scientific Advisory Board, International Academy of Cardiology	2000-
Scientific Advisory Board, 2 <sup>nd</sup> Int'l Congress on Heart Disease	2000-
Counselor, ACC South Carolina Chapter	2002-
Member, ACC Program Committee	2004-
Governor Member, ACCF Clinical Electrophysiology Committee	2006-
Awards Subcommittee, Heart Rhythm Society	2006-

## **PUBLICATIONS**

### **Journal Articles (Peer Reviewed)**

1. Gold MR, Cohen DH. Heart rate conditioning in the pigeon immobilized with bungarotoxin. *Brain Research* 1981;216:163-172.
2. Gold MR, Cohen DH. Modification of the discharge of vagal cardiac neurons during learned heart rate change. *Science* 1981;214:345-347.
3. Gold MR. The effects of vasoactive intestinal peptide on neuromuscular transmission in the frog. *J Physiol* 1982;327:325-335.
4. Gold MR, Martin AR. Intracellular Cl accumulation reduces Cl conductance in inhibitory synaptic channels. *Nature* 1982;299:828-830.
5. Gold MR, Martin AR. Inhibitory conductance changes at synapses in the brainstem of the lamprey. *Science* 1983;221:85-87.
6. Gold MR, Martin AR. Analysis of glycine-activated inhibitory postsynaptic channels in brainstem neurones of the lamprey. *J Physiol* 1983;342:85-98.
7. Gold MR, Martin AR. Characteristics of inhibitory postsynaptic currents in brainstem neurones of the lamprey. *J Physiol* 1983;342:85-98.
8. Does RM, Finger TE, Gold MR. Immunohistochemical localization of enkephalin- and ACTH-related substances in the pituitary of the lamprey. *Cell Tissue Res* 1984;235:107-115.
9. Gold MR, Martin AR.  $\gamma$ -Aminobutyric acid and glycine activate Cl<sup>-</sup> channels having different characteristics in CNS neurones. *Nature* 1984;308:639-641.
10. Gold MR, Cohen DH. The discharge characteristics of vagal cardiac neurons during classically conditioned heart rate change. *J Neuroscience* 1984;4:2963-2971.
11. Gold MR, Strichartz GR. Acute effects of repetitive depolarization on the sodium current in chick myocytes. *Am J Physiol* 1991;260:H1810-H1818.
12. Gold MR, Strichartz GR. Use-dependent block of atrial sodium currents by ethylisopropylamiloride. *J Cardiovas Pharm* 1991;17:792-799.
13. Gold MR, Dec GW, Cocca-Spofford D, Thompson BT. Effects of esmolol on ventilatory function in patients with chronic obstructive pulmonary disease. *Chest* 1991;100:1215-1218.
14. Salem M, Kasinski N, Andrei AM, Brussel T, Gold MR, Conn A, Chernow B. Hypomagnesemia is a frequent finding in emergency room patients with chest pain. *Arch Intern Med* 1991;151:2185-2190.

15. Powell AC, Gold MR, Garan H, Brooks R, Ruskin JN, McGovern BA. Electrophysiologic response to moricizine in patients with sustained ventricular arrhythmias. *Annals of Internal Medicine* 1992;116:382-387.
16. Peters RW, Buser GA, Kim HJ, Gold MR. Tricyclic overdose causing sustained monomorphic ventricular tachycardia. *Am J Cardiol* 1992;70:1226-1228.
17. Peters RW, Kim HJ, Buser GA, Gold MR. Ischemically mediated sustained monomorphic ventricular tachycardia. *Chest* 1993;104:1613-1614.
18. Gilbert TB, Kent JL, Foster AH, Gold MR. Implantable Cardioverter/Defibrillator Placement in a Patient with Amiodarone Pulmonary Toxicity under Thoracic Epidural Anesthesia. *Anesthesiology*, 1993;79:608-611.
19. Gottlieb SS, Lauria S, Riggio DW, Peters RW, Shorofsky SR, Cines M, Froman D, Gold MR. High dose oral amiodarone loading exerts important hemodynamic actions in patients with congestive heart failure. *J Am Coll Cardiol*, 1994;23:560-564.
20. Peters RW, Weiss DN, Carlner N, Feliciano Z, Shorofsky SR, Gold MR. Overdrive pacing for atrial flutter. *Am J Cardiol*, 1994;74:1021-1023.
21. Foster AH, Gold MR, McLaughlin JS. Acute hemodynamic effects of atrio-biventricular pacing in humans. *Ann Thorac Surg*, 1995;59:294-300.
22. Peters RW, Foster AH, Shorofsky SR, Nolan DA, Gold MR. Spurious discharges due to late insulation break in endocardial sensing leads for cardioverter defibrillators. *PACE*, 1995;18:478-481.
23. Silverman ME, Pressel MD, Brackett JC, Lauria SS, Gold MR, Gottlieb SS. Prognostic value of the signal-averaged electrocardiogram and a prolonged QRS in ischemic and nonischemic cardiomyopathy. *Am J Cardiol*, 1995;75:460-464.
24. Watson CL, Gold MR. Effect of intracellular and extracellular acidosis on sodium current in ventricular myocytes. *Am J Physiol*, 1995;268:H1749-H1756.
25. Riggio DW, Peters RW, Feliciano Z, Gottlieb SS, Shorofsky SR, Gold MR. Acute electrophysiologic effects of amiodarone in patients with congestive heart failure. *Am J Cardiol*, 1995;75:1158-1161.
26. Gold MR, Feliciano Z, Gottlieb SS, Fisher ML. Dual-chamber pacing with a short atrioventricular delay in congestive heart failure: a randomized study. *J Am Coll Cardiol*, 1995;26(4):967-973.
27. Reese DB, Silverman ME+, Gold MR, Gottlieb SS. Prognostic importance of the length of ventricular tachycardia in patients with nonischemic congestive heart failure. *Am Heart J*, 1995;130:489-493.

28. Krasna MJ, Buser GA, Flowers JL, Bailey R, *Gold MR*: Thoracoscopic versus laparoscopic placement of defibrillator patches. *Surg Laparosc & Endosc*, 1996;6:91-97.
29. *Gold MR*, Shorofsky SR. Transvenous defibrillation lead systems. *J Cardiovasc Electrophysiol*, 1996;7:570-580.
30. Weiss DN, *Gold MR*, Peters RW. Rate responsive pacing mimicking ventricular tachycardia. *J Invas Cardiol*, 1996;8:228-230.
31. Tummala RV, Riggio DR, Peters RW, Shorofsky SR, *Gold MR*. Chronic rise in defibrillation threshold in a hybrid lead system. *Am J Cardiol*, 1996;78:309-312.
32. Shorofsky SR, *Gold MR*. Effects of waveform and polarity on defibrillation thresholds in humans using a transvenous lead system. *Am J Cardiol*, 1996;78:313-316.
33. Foster MT, Peters RW, Froman D, Shorofsky SR, *Gold MR*. Electrophysiologic effects and predictors of success of combination therapy with class Ia and Ib antiarrhythmic drugs for sustained ventricular arrhythmias. *Am J Cardiol*, 1996;78:47-50.
34. *Gold MR*, Foster AH, Shorofsky SR. Effects of an active pectoral-pulse generator shell on defibrillation efficacy with a transvenous lead system. *Am J Cardiol*, 1996, 78:540-543.
35. Peters RW, McQuillan S, Resnick SK, *Gold MR*. Increased Monday incidence of life-threatening ventricular arrhythmias: experience with a third generation implantable defibrillator. *Circulation*, 1996;94:1346-1349.
36. *Gold MR*, Peters RW, Johnson JW, Shorofsky SR. Complications associated with pectoral cardioverter-defibrillator implantation: comparison of subcutaneous and submuscular approaches. *J Am Coll Cardiol*, 1996;28:1278-1282.
37. *Gold MR*, O'Gara PT, Buckley MJ, DeSanctis RW. Efficacy and safety of procainamide in preventing arrhythmias after coronary artery bypass surgery. *Am J Cardiol*, 1996;78:975-979.
38. Khalighi K+, Daly B, Leino EV, Shorofsky SR, Kavesh NG, Peters RW, *Gold MR*. Clinical predictors of transvenous defibrillation energy requirements. *Am J Cardiol*, 1997;79:150-153.
39. *Gold MR*, Peters RW, Johnson JW, Shorofsky SR. Complications associated with pectoral implantation of cardioverter-defibrillators. *PACE*, 1997;20:208-211.
40. *Gold MR*, Shorofsky SR, Metcalf MD+, Feliciano Z, Fisher ML, Gottlieb SS. The acute hemodynamic effects of right ventricular septal pacing in patients with congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. *Am J Cardiol*, 1997;79:679-681.
41. Kirk MM, Shorofsky SR, Khalighi K, Kavesh NG, Peters RW, *Gold MR*. Chronic rise in monophasic defibrillation thresholds with a transvenous lead system. *Am J Cardiol*,

1997;79:502-505.

42. Shorofsky SR, Foster AH, Gold MR. Effect of waveform tilt on defibrillation thresholds in humans. *J Cardiovasc Electrophysiol*, 1997;8:496-501.
43. Gold MR, Kavesh NG, Peters RW, Shorofsky SR. Biphasic waveforms prevent the chronic rise of defibrillation thresholds with a transvenous lead system. *J Am Coll Cardiol*, 1997;30:233-236.
44. Khalighi K, Florin TJ, Peters RW, Shorofsky SR, Gold MR. Distortion of intracardiac electrograms following defibrillator shocks for atrial tachyarrhythmias. *PACE*, 1997;20:1682-1685.
45. Gold MR, Khalighi K, Kavesh NG, Daly B, Peters RW, Shorofsky SR. Clinical predictors of transvenous biphasic defibrillation thresholds. *Am J Cardiol* 1997;79:1623-1627.
46. Peters RW, Gilbert TB, Johns-Walton S, Gold MR. Lidocaine-related increase in defibrillation threshold. *Anesth Analg*, 1997;85:299-300.
47. Watson CL, Gold MR. Lysophosphatidylcholine modulates cardiac  $I_{Na}$  via multiple protein kinase pathways. *Circ Res*, 1997;81:387-395.
48. Watson CL, Gold MR. Modulation of  $Na^+$  current inactivation by stimulation of protein kinase C in cardiac cells. *Circ Res*, 1997;81:380-386.
49. Khalighi K, Peters RW, Feliciano Z, Shorofsky SR, Gold MR. Comparison of class Ia/Ib versus class III antiarrhythmic drugs for the suppression of inducible sustained ventricular tachycardia associated with coronary artery disease. *Am J Cardiol* 1997;80:591-594.
50. Florin TJ, Weiss DN, Peters RW, Shorofsky SR, Gold MR. Induction of atrial fibrillation with low-energy defibrillator shocks in patients with implantable cardioverter defibrillators. *Am J Cardiol* 1997;80:960-962.
51. Olsovsky MR, Hodgson DM, Shorofsky SR, Kavesh NG, Gold MR. Effect of biphasic waveforms on transvenous defibrillation thresholds in patients with coronary artery disease. *Am J Cardiol* 1997;80:1098-1100.
52. Gold MR, Shorofsky SR. Strength duration relationship for human transvenous defibrillation. *Circulation*, 1997;96:3517-3520.
53. Kavesh NG, Gosnell MR, Shorofsky SR, Gold MR. Comparison of power- and temperature-guided radiofrequency modification of the atrioventricular node. *Am J Cardiol*, 1997;80:1444-1447.
54. Gold MR, Foster AH, Shorofsky SR. Lead system optimization for transvenous defibrillation. *Am J Cardiol*, 1997;80:1163-1167.
55. Freed LA, Eagle KA, Mahjoub ZA, Gold MR, Smith AJ C, Terrell LB, O'Gara PT, Paul

- SD. Gender differences in presentation, management, and cardiac event-free survival in patients with syncope. *Am J Cardiol*, 1997;80:1183-1187.
56. Peters RW, Kavesh N, Pelini M, Gold MR. Permanent pacing from the coronary sinus in a patient with an implantable defibrillator. *PACE* 1997;20(Pt. I):2286--2287.
57. Olsovsky MR, Pelini MA, Shorofsky SR, Gold MR. Temporal stability of defibrillation thresholds with an active pectoral lead system. *J Cardiovasc Electrophysiol*, 1998;9:240-244.
58. Olsovsky MR, Shorofsky SR, Gold MR. Effect of shock polarity on biphasic defibrillation thresholds using an active pectoral lead system. *J Cardiovasc Electrophysiol*, 1998;9:350-354.
59. Gold MR, Olsovsky MR, Pelini MA, Peters RW, Shorofsky SR. Comparison of single- and dual-coil active pectoral defibrillation lead systems. *J Am Coll Cardiol*, 1998;31:1391-1394.
60. Peters RW, Gold MR. Reversible prolonged pacemaker failure due to electrocautery. *J Interventional Card Electrophysiol*, 1998;2:343-344.
61. Gold MR, Froman D, Kavesh NG, Peters RW, Foster AH, Shorofsky SR. A comparison of pectoral and abdominal transvenous defibrillator implantation: analysis of costs and outcomes. *J Interventional Card Electrophysiol*, 1998;2:345-349.
62. Peters RW, Cooklin M, Brockman R, Shorofsky SR, Gold MR. Inappropriate shocks from implanted cardioverter defibrillators caused by sensing of diaphragmatic myopotentials. *J Interventional Card Electrophysiol*, 1998;2:367-370.
63. Kavesh NG, Shorofsky SR, Sarang SE, Gold MR. Effect of heart rate on T wave alternans. *J Cardiovasc Electrophysiol*, 1998;9:703-708.
64. Weiss DN, Shorofsky SR, Peters RW, Gold MR. The effect of delivered energy on defibrillation shock impedance. *J Interventional Card Electrophysiol*, 1998;2:273-277.
65. Peters RW, Shorofsky SR, Pelini M, Olsovsky M, Gold MR. Overdrive atrial pacing for conversion of atrial flutter: comparison of postoperative with nonpostoperative patients. *Am Heart J* 1999;137:100-103.
66. Olsovsky MR, Shorofsky SR, Gold MR. The effect of shock configuration and delivered energy on defibrillation impedance. *PACE* 1999;22(II):165-168.
67. Gold MR, Hsu W, Marcovecchio AF, Olsovsky MR, Lang DJ, Shorofsky SR. A new defibrillator discrimination algorithm utilizing electrogram morphology analysis. *PACE* 1999;22(II):179-182.
68. Buxton AE, Hafley GE, Lehmann MH, Gold MR, O'Toole M, Tang A, Coromilas J, Hook B, Stamato NJ, Lee KL. Prediction of sustained ventricular tachycardia inducible by

- programmed stimulation in patients with coronary artery disease (utility of clinical variables). *Circulation* 1999;99:1843-1850.
69. Kavesh NG, Olsovsky MR, Freudenberger RS, Conte JV, Peters RW, Shorofsky SR, *Gold MR*. Intravenous amiodarone suppression of electrical storm refractory to chronic oral amiodarone. *PACE* 1999;22:665-667.
  70. Kavesh NG, Shorofsky SR, Sarang SE, *Gold MR*. The effect of procainamide on T-wave alternans. *J Cardiovasc Electrophysiol*, 1999;10:649-654.
  71. Benitez RM, *Gold MR*. Immediate and persistent complete heart block following a horse kick. *PACE* 1999;22:816-818.
  72. Cooklin M, Tummala RV, Peters RW, Shorofsky SR, *Gold MR*. Comparison of bipolar and integrated sensing for redetection of ventricular fibrillation. *Am Heart J* 1999;138:133-136.
  73. Cooklin M, Olsovsky MR, Brockman RG, Shorofsky SR, *Gold MR*. Atrial defibrillation with a transvenous lead: A randomized comparison of active can shocking pathways. *J Am Coll Cardiol* 1999;34:358-362.
  74. Peters RW, McQuillan S, *Gold MR*. Interaction of septadian and circadian rhythms in life-threatening ventricular arrhythmias in patients with implantable cardioverter-defibrillators. *Am J Cardiol* 1999;84:555-557.
  75. Degeratu FT, Khalighi K, Peters RW, Shorofsky SR, *Gold MR*. Sensing lead failure in implantable defibrillators: A comparison of two commonly used leads. *J Cardiovasc Electrophysiol* 2000;11:21-24.
  76. *Gold MR*, Olsovsky MR, DeGroot PJ, Cuello C, Shorofsky SR. Optimization of transvenous coil position for active can defibrillation thresholds. *J Cardiovasc Electrophysiol* 2000;11:25-29.
  77. Kavesh NG, Sarang SE, *Gold MR*. Signal-averaged isoharmonic body surface maps of patients with ischemic cardiomyopathy. *J Cardiovasc Electrophysiol* 2000;11:160-167.
  78. *Gold MR*, Brockman R, Peters RW, Olsovsky MR, Shorofsky SR. Acute hemodynamic effects of right ventricular pacing site and pacing mode in patients with congestive heart failure. *Am J Cardiol* 2000;85:1106-1109.
  79. Buxton AE, Lee KL, DiCarlo L, *Gold MR*, Greer GS, Prystowsky EN, O'Toole MF, Tang A, Fisher JD, Coromilas J, Talajic M, Hafley G for the Multicenter UnSustained Tachycardia Trial Investigators. Utility of electrophysiologic testing to identify patients with coronary artery disease at risk of sudden death. *N Engl J Med* 2000; 342:1937-1945.
  80. Pelini M, Peters RW, Khalighi K, Shorofsky SR, *Gold MR*. Short term escape rhythm characteristics after radiofrequency ablation of the atrioventricular junction. *J Interventional Card Electrophysiol*, 2000;4:301-305.

81. Shorofsky SR, Gold MR. The effect of second phase duration on the strength-duration relation for human transvenous defibrillation. *Circulation*, 2000;102:2239-2242.
82. Gold MR, Bloomfield DM, Anderson KP, El-Sherif NE, Wilber DJ, Groh WJ, Estes NAM, Kaufman ES, Greenberg ML, Rosenbaum DS. A comparison of T-wave alternans, signal-averaged electrocardiography and programmed ventricular stimulation for arrhythmia risk stratification. *J Am Coll Cardiol*, 2000;36:2247-2253.
83. Gold MR, Nisam S. Primary prevention of sudden cardiac death with implantable cardioverter defibrillators: Lessons learned from MADIT and MUSTT. *PACE*, 2000;23:1981-1985.
84. Kron J, Herre J, Renfroe EG, Rizo-Patron C, Raitt M, Halperin B, Gold MR, Goldner B, Wathen M, Wilkoff B, Olarte A, Yao Q, and the AVID Investigators. Lead- and device-related complications in the antiarrhythmics versus implantable defibrillators trial. *Am Heart J* 2001;141:92-98.
85. Exner DV, Pinski SL, Wyse G, Renfroe EG, Follmann D, Gold MR, Beckman KJ, Coromilas J, Lancaster S, Hallstrom AP and the AVID Investigators. Electrical storm presages non-sudden death: the antiarrhythmics versus implantable defibrillators (AVID) trial. *Circulation* 2001;103:2066-2071.
86. Rashba EJ, Olsovsky MR, Shorofsky SR, Kirk MM, Peters RW, Gold MR. Temporal decline in defibrillation thresholds with an active pectoral lead system. *J Am Coll Cardiol* 2001;38:1150-1155.
87. Rashba EJ, Bouhouch R, Koshy S, MacMurdy K, Shorofsky SR, Peters RW, Gold MR. A new algorithm for transthoracic cardioversion of atrial fibrillation based on body weight. *Am J Cardiol* 2001;88:1043-1045.
88. Gold MR, Sulke N, Schwartzman DS, Mehra R, Euler DE. Clinical experience with a dual-chamber implantable cardioverter defibrillator to treat atrial tachyarrhythmias. *J Cardiovasc Electrophysiol* 2001;12:1247-1253.
89. Kirk MM, Shorofsky SR, Gold MR. Comparison of the effects of active left and right pectoral pulse generators on defibrillation efficacy. *Am J Cardiol* 2001;88:1308-1311.
90. Hodgson DM, Olsovsky MR, Shorofsky SR, Daly B, Gold MR. Clinical predictors of defibrillation thresholds with an active pectoral pulse generator lead system. *PACE* 2002;25:408-413.
91. Rashba EJ, Bouhouch R, MacMurdy KA, Shorofsky SR, Peters RW, Gold MR. Effect of shock polarity on the efficacy of transthoracic atrial defibrillation. *Am Heart J* 2002;143:541-545.
92. Newman DM, Dorain P, Paquette M, Sulke N, Gold MR, Schwartzman DS, Schaff K, Wood K, Johnson L. The effect of an implantable cardioverter defibrillator with atrial

- detection and shock therapies on patient perceived health-related quality of life. *Am Heart J* 2002;145:841-846.
93. Rashba EJ, Cooklin M, MacMurdy K, Kavesh N, Kirk M, Sarang S, Peters RW, Shorofsky SR, Gold MR. Effects of selective autonomic blockade on T wave alternans in humans. *Circulation* 2002;105:837-842.
  94. Gold MR, Shorofsky SR, Bouhouch R, Joy RA, Kirby DS, Osman AF, Rashba EJ. Lack of benefit of an active pectoral pulse generator on atrial defibrillation thresholds. *J Cardiovasc Electrophysiol* 2002;13:332-335.
  95. Kirby DS, Gold MR, Rashba EJ, Shorofsky SR. Postentrainment activation sequence: Diagnostic of the supraventricular tachycardia mechanism? *J Cardiovasc Electrophysiol* 2002;13:410-412.
  96. Gold MR, Higgins S, Klein R, Gilliam FR, Kopelman H, Hessen S, Payne J, Strickberger SA, Breiter D, Hahn S. Efficacy and temporal stability of reduced safety margins for ventricular defibrillation. Primary results from the Low Energy Safety Study (LESS). *Circulation* 2002; 105:2043-2048.
  97. Gilbert TB, Gold MR, Shorofsky SR, Hasnain JU, Ferguson MK, Foster AH. Cardiovascular responses to repetitive defibrillation during implantable cardioverter-defibrillator testing. *J Cardiothorac Vasc Anesth* 2002;16:180-185.
  98. Lee KL, Hafley G, Fisher JD, Gold MR, Prystowsky EN, Talajic M, Josephson ME, Packer DL, Buxton AE for the Multicenter Unsustained Tachycardia Trial Investigators. Effect of implantable defibrillators on arrhythmic events and mortality in the multicenter unsustained tachycardia trial. *Circulation* 2002;106:233-238.
  99. Rashba EJ, Osman AF, Macmurdy K, Kirk MM, Sarang S, Peters RW, Shorofsky SR, Gold MR. Influence of QRS duration on the prognostic value of T wave alternans. *J Cardiovasc Electrophysiol* 2002;13:770-775.
  100. Rashba EJ, Osman AF, Macmurdy K, Kirk MM, Sarang S, Peters RW, Shorofsky SR, Gold MR. Exercise is superior to pacing for T wave alternans measurement in subjects with chronic coronary artery disease and left ventricular dysfunction. *J Cardiovasc Electrophysiol* 2002;13:845-850.
  101. Buxton AE, Lee KL, Hafley GE, Wyse G, Fisher JD, Lehmann MH, Pires LA, Gold MR, Packer DL, Josephson ME, Prystowsky EN, Talajic MR; for the MUSTT Investigators. Relation of ejection fraction and inducible ventricular tachycardia to mode of death in patients with coronary artery disease (an analysis of patients enrolled in the multicenter unsustained tachycardia trial). *Circulation* 2002;106:2466-2472.
  102. Gold MR, Shorofsky SR, Thompson JA, Kim J, Schwartz M, Bocek J, Lovett EG, Hsu W, Morris MM, Lang DJ. Advanced rhythm discrimination for implantable cardioverter defibrillators using electrogram vector timing and correlation. *J Cardiovasc Electrophysiol* 2002;13:1092-1097.

103. Carlson MD, Ip J, Messenger J, Beau S, Kalbfleisch S, Gervais P, Cameron DA, Duran A, Val-Mejias J, Mackall J, *Gold MR* for the ADOPT Investigators. A new pacemaker algorithm for the treatment of atrial fibrillation. *J Am Coll Cardiol* 2003;42:627-633.
104. Prystowsky EN, Niazi I, Curtis AB, Wilber DJ, Bahnson T, Ellenbogen K, Dhala A, Bloomfield DM, *Gold MR*, Kadish A, Fogel RI, Gonzalez MD, Belardinelli L, Shreenivas R, Wolff AA. Termination of paroxysmal supraventricular tachycardia by tecadenoson (CVT-510), a novel A<sub>1</sub>-Adenosine receptor agonist. *J Am Coll Cardiol* 2003;42:1098-1102.
105. Rashba EJ, Bonner M, Wilson J, Shorofsky SR, Peters RW, *Gold MR*. Distal right ventricular coil position reduces defibrillation thresholds. *J Cardiovasc Electrophysiol* 2003;14:1036-1040.
106. Stambler BS, Ellenbogen KA, Zhang X, Porter TR, Xie F, Malik R, Small R, Burke M, Kaplan A, Nair L, Belz M, Fuenzalida, *Gold MR*, Love C, Sharma A, Silverman R, Sogade F, Natta BV and Wilkoff BL for the ROVA Investigators. Right ventricular outflow versus apical pacing in pacemaker patients with congestive heart failure and atrial fibrillation. *J Cardiovasc Electrophysiol* 2003;14:1180-1186.
107. *Gold MR*, Breiter D, Leman R, Rashba EJ, Shorofsky SR, Hahn SJ. Safety of a single successful conversion of ventricular fibrillation before the implantation of cardioverter defibrillators. *PACE* 2003;26 (1 Pt 2):483-486.
108. Rashba EJ, Shorofsky SR, Peters RW, *Gold MR*. Effect of shock polarity on defibrillation thresholds with a hybrid patch-coil lead system. *J Interv Card Electrophysiol* 2003;9(3):391-396.
109. Shorofsky SR, Peters RW, Rashba EJ, *Gold MR*. Comparison of step-down and binary-search algorithms for determination of defibrillation threshold in humans. *PACE* 2004;27:218-220.
110. Freudenberger R, Sikora J, Fisher M, Wilson A, *Gold MR*. Electrocardiogram and clinical characteristics of patients referred for cardiac transplantation: implications for pacing in heart failure. *Clin Cardiol* 2004;27:151-153.
111. Rashba EJ, Osman AF, Macmurdy K, Kirk MM, Sarang SE, Peters RW, Shorofsky SR, *Gold MR*. Enhanced detection of arrhythmia vulnerability using T wave alternans, left ventricular ejection fraction, and programmed ventricular stimulation: a prospective study in subjects with chronic ischemic heart disease. *J Cardiovasc Electrophysiol* 2004;15:170-176.
112. Page RL, Zipes DP, Powell JL, Luceri RM, *Gold MR*, Peters R, Russo AM, Bigger JT, Sung RJ, McBurnie MA and the AVID Investigators. Seasonal variation of mortality in the antiarrhythmics versus implantable defibrillators (AVID) study registry. *Heart Rhythm* 2004;4:435-440.

113. Rashba EJ, Shorofsky SR, Peters RW, *Gold MR*. Optimization of atrial defibrillation with a dual-coil, active pectoral lead system. *J Cardiovasc Electrophysiol* 2004;15:790-794.
114. Rashba EJ, Shorofsky SR, Brown T, Peters RW, *Gold MR*. Clinical predictors of atrial defibrillation thresholds with a dual-coil, active pectoral lead system. *Heart Rhythm* 2005;2:49-54.
115. Schwartzman D, *Gold MR*, Quesada A, Koehler JL, Mehra R, Euler DE for the Worldwide Jewel AF-Only Investigators. Serial evaluation of atrial tachyarrhythmia burden and frequency after implantation of a dual-chamber cardioverter-defibrillator. *J Cardiovasc Electrophysiol* 2005;16:708-713.
116. *Gold MR*, Auricchio A, Hummel JD, Giudici MC, Ding J, Tockman B, Spinelli J. Comparison of stimulation sites within left ventricular veins on the acute hemodynamic effects of cardiac resynchronization therapy. *Heart Rhythm* 2005;2:376-381.
117. Shorofsky SR, Rashba E, Havel W, Belk P, Degroot P, Swerdlow C, *Gold MR*. Improved defibrillation efficacy with an ascending ramp waveform in humans. *Heart Rhythm* 2005;2:388-394.
118. Linde C, *Gold MR*, Abraham WT, Daubert JC for the REVERSE Study Group. Rationale and design of a randomized controlled trial to assess the safety and efficacy of cardiac resynchronization therapy in patients with asymptomatic left ventricular dysfunction with previous symptoms or mild heart failure-the REsynchronization reVERses Remodeling in Systolic left vEntricular dysfunction (REVERSE) study. *American Heart Journal* 2006;151:288-294.
119. Rashba EJ, Farasat M, Kirk MM, Shorofsky SR, Peters RW, *Gold MR*. Effect of an active abdominal pulse generator on defibrillation thresholds with a dual-coil, transvenous ICD lead system. *J Cardiovasc Electrophysiol* 2006;17:617-620.
120. Berger RD, Lerew DR, Smith JM, Pulling C, *Gold MR*. The rhythm ID going head to head trial (RIGHT): design of a randomized trial comparing competitive rhythm discrimination algorithms in implantable cardioverter defibrillators. *J Cardiovasc Electrophysiol* 2006;17:749-753.
121. *Gold MR*, Hoffmann E; SAFARI Investigators. Rationale and design of a randomized clinical trial to assess the role of overdrive and triggered prevention pacing therapies in reducing atrial fibrillation: the study of atrial fibrillation reduction (SAFARI). *American Heart Journal* 2006;152(2):231-236.
122. Hohnloser SH, Capucci A, Fain E, *Gold MR*, Van Gelder I, Healey J, Israel C, Lau C, Morillo C, Connolly SJ. Asymptomatic atrial fibrillation and stroke evaluation in pacemaker patients and the atrial fibrillation reduction atrial pacing trial (ASSERT). *American Heart Journal* 2006;152:442-447.

123. Martin DO, Stolen KQ, Brown S, Yu Y, Christie C, Doshi SK, Smith JM, *Gold MR*, Day JD. Pacing evaluation-atrial support study in cardiac resynchronization therapy (PEGASUS CRT): design and rationale. *American Heart Journal* 2007;153:7-13.
124. *Gold MR*, Niazi I, Giudici M, Leman RB, Sturdivant JL, Kim MH, Yu Y, Ding J, Waggoner AD. A prospective comparison of AV delay programming methods for hemodynamic optimization during cardiac resynchronization therapy. *J Cardiovasc Electrophysiol* 2007;18:490-496.
125. Al-Khatib SM, Sanders GD, Bigger JT, Buxton AE, Califf RM, Carlson M, Curtis A, Curtis J, Fain E, Gersh BJ, *Gold MR*, Haghighi-Mood A, Hammill SC, Healey J, Hlatky M, Hohnloser S, Kim RJ, Lee K, Mark D, Mianulli M, Mitchell B, Prystowsky EN, Smith J, Steinhaus D, Zareba W. Preventing tomorrow's sudden cardiac death today: Part I: current data on risk stratification for sudden cardiac death. *American Heart Journal* 2007;153:941-950.
126. Sanders GD, Al-Khatib SM, Berliner E, Bigger JT, Buxton AE, Califf RM, Carlson M, Curtis AB, Curtis JP, Domanski M, Fain E, Gersh BJ, *Gold MR*, Goldberger J, Haghighi-Mood A, Hammill SC, Harder J, Healey J, Hlatky MA, Hohnloser SH, Kim RJ, Lee KL, Mark DB, Mitchell B, Phurrough S, Prystowsky EN, Smith JM, Stockbridge N, Temple R. Expert panel participating in a Duke Center for the prevention of sudden cardiac death-sponsored conference. Preventing tomorrow's sudden cardiac death today: Part II: translating sudden cardiac death risk assessment strategies into practice and policy. *American Heart Journal* 2007;153(6):951-959.
127. Schuchert A, Carlson M, Ip J, Messenger J, Beau S, Kalbfleisch S, Gervais P, Cameron DA, Duran A, Val-Mejias J, Mackall J, *Gold MR* for the ADOPT Investigators. Atrial overdrive pacing and incidence of heart failure-related adverse events in permanently paced patients. *J Interv Card Electrophysiol* 2007;19:55-60.
128. Buxton, AE, Lee KL, Hafley GE, Pires LA, Fisher JD, *Gold MR*, Josephson ME. Limitations of ejection fraction for prediction of sudden death risk in patients with coronary artery disease. Lessons from the MUSTT study. *J Am Coll Cardiol* 2007;50:1150-1157.
129. Giada F, Barold SS, Biffi A, Piccoli BD, Delise P, El-Sherif N, *Gold MR*, Gorenek B, Grubb B, Inama G, Kautzner J, Molina L, Olshansky, Pelliccia A, Thiene G, Wellens H, Wolpert C, Zeppilli P, Raviele A, Heidbuchel H. Sport and arrhythmias: summary of an international symposium. *Eur J Cardiovasc Prev Rehabil* 2007;14:707-714.
130. *Gold MR*, Val-Mejias J, Leman RB, Tummala R, Goyal S, Kluger J, Kroll M, Oza A. Optimization of superior vena cava coil position and usage for transvenous defibrillation. *Heart Rhythm* 2008;5:394-399.
131. Linde C, *Gold MR*, Abraham WT, Daubert JC. Baseline characteristics of patients randomized in the resynchronization reverses remodeling in systolic left ventricular dysfunction (REVERSE) study. *Congest Heart Fail.*2008;14:66-74.

132. Linde C, Abraham WT, Gold MR, Sutton M SJ, Daubert C on behalf of the REVERSE (Resynchronization reverses Remodeling in Systolic left vEntricular dysfunction) Study Group. Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. *J Am Coll Cardiol* 2008;52:1834-1843.
133. Cuoco FA, Spencer WH, Fernandes VL, Nielsen CD, Nagueh S, Sturdivant JL, Leman RB, Wharton, JM, Gold MR. Implantable cardioverter-defibrillator therapy for primary prevention of sudden death after alcohol septal ablation of hypertrophic cardiomyopathy. *J Am Coll Cardiol* 2008;52:1718-1723.
134. Gold MR, Ip JH, Costantini O, Poole JE, McNulty S, Mark DB, Lee KL, Bardy GH. Role of microvolt T-wave alternans in assessment of arrhythmia vulnerability among patients with heart failure and systolic dysfunction (primary results from the T-wave alternans sudden cardiac death in heart failure trial substudy) *Circulation* 2008;118:2022-2028.
135. Simon RDB, Sturdivant JL, Leman RB, Wharton JM, Gold MR. The effect of dofetilide on ventricular defibrillation thresholds. *PACE* 2009;32:24-28.
136. Serber ER, Finch NJ, Leman RB, Sturdivant LJ, Barnes T, Clarke E, Garry J, Gold MR. Disparities in preferences for receiving support and education among patients with implantable cardioverter defibrillators. *PACE* 2009;32:383-390.
137. Gold MR, Kroll MW, Ellenbogen KA. Defibrillation testing at ICD implantation: are we asking the wrong question? *In Press*
138. Gold MR, Adler S, Fauchier L, Haffajee C, Ip J, Kainz W, Kawasaki R, Prakash A, Taborsky M, Waller T, Wilson V, Li S, Hoffman E, for the SAFARI Investigators. Impact of atrial prevention pacing on atrial fibrillation burden: primary results of the study of atrial fibrillation reduction (SAFARI) trial. *Heart Rhythm* 2009;6:295-301.

Journal Articles (Non-Peer Reviewed)

1. Balke CW, Gold MR. Calcium channels in the heart: an overview. *Heart Disease & Stroke* 1992;1:398-403. 1992;1:398-403.
2. Peters RW, Gold MR. Arrhythmias developing after coronary artery bypass surgery. *Cardio* 1992;9:31-40.
3. Balke CW, Gold MR. Excitation-contraction-relaxation coupling in the normal and failing heart. *Heart Disease & Stroke* 1993;2:89-177.
4. Gold MR, Balke CW. The Cellular Action of Antiarrhythmic Drugs. *Heart Disease & Stroke* 1993;2:434-438.
5. Gold MR, DeSanctis RW. Procainamide: Effective Prophylactic for Arrhythmias after Bypass Surgery. *Cardiology Review* 1997;14:23-28.

6. Cooklin M, Gold MR. Implications and treatment of atrial fibrillation after cardiothoracic surgery. *Current Opinion in Cardiology* 1998;13:20-28.
7. Kirk MM, Gold MR. Disopyramide. *Cardiac Electrophysiology Review* 1998;2:189-190.
8. Gold MR. Optimization of ventricular pacing: Where should we implant the leads? *JACC* 1999;33:324-326.
9. Gold MR, Peters RW. Permanent pacemakers in patients with dilated cardiomyopathy. *Cardiac Electrophysiology Review* 1999;2:381-383.
10. Gold MR, Josephson ME. Cardiac arrhythmia: current therapy. *Hospital Practice* 1999;34:27-42.
11. Gold MR, Rashba EJ. Left ventricular endocardial pacing: Don't try this at home. *PACE* 1999;22:1567-1569.
12. Kirk MM, Gold MR. Disopyramide phosphate. *Cardiac Electrophysiology Review* 2000;4:269-271.
13. Peters RW, Gold MR. Pacing for patients with congestive heart failure and dilated cardiomyopathy. *Cardiology Clinics* 2000;18:55-66.
14. Gold MR. ICD therapy in the new millennium. *Cardiology Clinics* 2000;18:375-389.
15. Peters RW, Gold MR. Implantable cardiac defibrillators. *Med Clin North Am.* 2001;85:343-367.
16. Gold MR. Permanent pacing: new indications. *Heart.* 2001;86:355-360.
17. Rashba EJ, Gold MR. Correlation waveform analysis of the atrial signal: the shape of things to come? *J Cardiovasc Electrophysiol* 2001;12:150-152.
18. Osman AF, Gold MR. T wave alternans for ventricular arrhythmia risk stratification. *Current Opinion Cardiol* 2002;17:1-6.
19. Shorofsky SR, Gold MR. T wave alternans: predictor of arrhythmic events? Fact or Fiction *J Cardiovasc Electrophysiol* 2002;13:513-514.
20. Gold MR, Spencer W. T wave alternans for ventricular arrhythmia risk stratification. *Current Opinion in Cardiol* 2003;18:1-5.
21. Peters RW, Gold MR. Permanent pacemakers and antiarrhythmic devices. *Intensive Care Medicine* 5<sup>th</sup> Edition 2003:460-473.
22. Sturdivant JL, Gold MR. T wave alternans for ventricular arrhythmia risk stratification. Estratto da *MINVERVA CARDIOANGIOLOGICA* 2003;51:15-19.

23. *Gold MR*. Diagnosis and Treatment of Arrhythmias (Section Editor-Clinical Trials Report). *Current Cardiology Reports* 2003;5:347-349.
24. *Gold MR*, *Leman RB*, *Euler DE*. Effectiveness of rapid atrial pacing for termination of drug refractory atrial fibrillation: Results of a dual chamber implantable cardioverter defibrillator trial. *Cardiac Electrophysiology Review* 2003;7:341-344.
25. *Gold MR*, *Peters RW*. Newer applications of pacemakers. *Cardiac Electrophysiology From Cell to Bedside 4th Edition* 2004:1011-1017.
26. *Gold MR*. Diagnosis and Treatment of Arrhythmias (Section Editor-Clinical Trials Report). *Current Cardiology Reports* 2004;6:319-321.
27. *Peters RW*, *Gold MR*. Method of Heart Block. *Rakel and Bope: Conn's Current Therapy* 2005;349.
28. *Simon DB*, *Burke SW*, *Gold MR*. Iatrogenic ventricular dyssynchrony: a preventable cause of heart failure with right ventricular pacing? *Heart Rhythm* 2005;2:252-253.
29. *Colley BJ*, *Gold MR*. Assessment of single-shock defibrillation testing of biventricular ICD's. *S. Serge Barold and Philippe Ritter. Devices for Cardiac Resynchronization Technologic and Clinical Aspects.* 2008;269-279.
30. *Klein MH*, *Gold MR*. Use of traditional and biventricular implantable cardiac devices for primary and secondary prevention of sudden death. *Cardiol Clin* 26;2008;419-431.
31. *Gold MR*, *Cho Y*, *Bennett T*. Heart failure management monitoring with implantable devices. *Asian Hospital & Healthcare Management* 17;2008;29-33.
32. *Forcina MS*, *Gold MR*. Role of cardiac resynchronization therapy in asymptomatic and mildly symptomatic heart failure. *Current Heart Failure Reports* 2009;6:44-48.

#### Chapters in Books

1. *Gold MR*. The action of vasoactive intestinal peptide at the frog's neuromuscular junction. In: *Chan Palay V, Palay SL, eds. Coexistence of neuroactive substances in neurons.* New York, NY: Wiley and Sons. 1984:161-170.
2. *Kastor JA*, *Gold MR*. Accelerated Junctional Rhythm. In: *Kastor JA. Arrhythmias.* Philadelphia, PA: W.B. Saunders Company. 1994;201-217.
3. *Gold MR*, *Peters RW*. Tachycardias. In: *Rakel RE. Conn's Current Therapy.* Philadelphia, PA: W.B. Saunders Company. 1995;236-241.
4. *Gold MR*. Antitachycardia Pacing and the Implantable Cardioverter-Defibrillator. In: *Ellenbogen KA. (ed) Cardiac Pacing.* Cambridge, MA: Blackwell Science. 1996;429-455.

5. Gold MR. The implantable cardioverter defibrillator. Ellenbogen KA, Wood MA (eds) *Cardiac Pacing and ICD's* (third edition). 2002; 399-433.
6. Gold MR, Peters RW. How great is the arrhythmic risk for heart failure patients and does resynchronization therapy modify it? In *Cardiac Arrhythmias 2001* Raviele A (ed), Springer, Milan, 2002; 151-156.
7. Peters RW, Gold MR. Permanent pacemakers and antiarrhythmic devices. *Irwin and Rippe's Intensive Care Medicine Fifth Edition*. Lippincott Williams & Wilkins. 2003;460-473.
8. Gold MR, Wharton MJ. Clinical pacemakers trials in systolic cardiac dysfunction: nonresynchronization. *Device Therapy for Congestive Heart Failure*. W.B. Saunders Company. 2004;92-103.
9. Gold MR, Casavant DA. Future trends in pacemaker technology. *The Fifth Decade of Cardiac Pacing*. Futura Blackwell Publishing. 2004;149-157.
10. Gold MR. The Implantable Cardioverter Defibrillator. In: Ellenbogen KA. and Wood MA (ed) *Cardiac Pacing and ICD's 4<sup>th</sup> Edition*. Cambridge, MA: Blackwell Science. 2005;380-414.
11. Doll JR, Gold MR. Permanent pacemakers and antiarrhythmic devices. *Manual of Intensive Care Medicine 4<sup>th</sup> Edition*. Irwin RS and Rippe JM. 2006;236-241.
12. Gold MR, DeGroot PJ. Optimization of defibrillation function. *New Arrhythmia Technologies*. Wang. 2005;197-205.

#### Abstracts

1. Gold MR, Cohen DH. Responses of vagal motoneurons. *Fed Proceed* 1979;38:1200.
2. Gold MR, Cohen DH. Discharge properties of vagal cardiac neurons during conditioned heart rate change. *Soc Neuroscience Abstracts* 1979;5:43.
3. Gold MR, Martin AR. VIP increases quantal content at the neuromuscular junction. *Soc Neuroscience Abstracts* 1980;6:842.
4. Gold MR, Finger TE. Localization of enkephalin-like immunoreactivity in the brain of the lamprey. *Soc Neuroscience Abstracts* 1982;7:85.
5. Gold MR, Martin AR. Characteristics of inhibitory synapses in the brainstem of the lamprey. *J Physiol* 1982;332:19P-20P.
6. Does RM, Finger TE, Gold MR, Immunohistochemical localization of enkephalin-and ACTH-related substances in the adenohypophysis of the lamprey. *Soc Neuroscience Abstracts* 1982;8:98.

7. Gold MR, Martin AR. Analysis of inhibitory postsynaptic currents in the brainstem of the lamprey. *Soc Neuroscience Abstracts* 1982;8:832.
8. Martin AR, Gold MR. Characteristics of glycine activated channels in lamprey brainstem neurons. *Soc Neuroscience Abstracts* 1982;8:832.
9. Martin AR, Gold MR. Anomalous behavior of glycine activated C1- channels in lamprey brainstem neurons. *Biophys J* 1983;41:62a.
10. Gold MR, Martin AR. Comparison of glycine and GABA channels in CNS neurons of the lamprey. *The Physiologist* 1983;2:A110.
11. Gold MR, Martin AR. Inhibitory channels in lamprey brainstem neurons activated by glycine and  $\gamma$ -amino butyric acid. *Proc 29th Internat Physiol Congress* 1983;15:89.
12. Gold MR, Strichartz GR. The effects of repetitive stimulation on the sodium current of chick heart cells. *Biophys J* 1989;55:44a.
13. Gold MR, Dec GW, Cocca-Spofford D, Thompson BT. Acute intravenous beta blockade with esmolol in cardiac patients with chronic obstructive pulmonary disease. *J Am Coll Cardiol* 1990;15:24A.
14. Gold MR, Strichartz GR. A comparison of the effects of lidocaine on atrial and ventricular and sodium currents. *J Mol Cell Cardiol* 1990;22:S14.
15. Gold MR, Dec GW, Cocca-Spofford D, Thompson BT. Safety of beta blockade in cardiac patients with chronic obstructive pulmonary disease. *Circulation* 1990;82:III-390.
16. Gold MR, Strichartz GR. Use-dependent block of sodium current with ethylisopropylamiloride. *Circulation* 1990;82:III-527.
17. Gold MR, Strichartz GR. The effect of pH on phasic properties of cardiac sodium currents. *Biophys J* 1991;59:545A.
18. Gold MR, Garan H, McGovern BA, Ruskin JN. Predictive value of low noise signal-averaged ECG for the induction of ventricular arrhythmias. *J Am Coll Cardiol* 1991;17:(2)97A.
19. Gold MR, Ungaro MA, Ory DS, O'Gara PT, Buckley MJ, DeSanctis RW. Procainamide prevents arrhythmias following coronary bypass surgery. *Circulation* 1991;84:II-285.
20. Gold MR, Ungaro MA, Buckley MJ, DeSanctis RW. Predictors of the antiarrhythmic action of procainamide following cardiac surgery. *J Am Coll Cardiol* 1992;19:112A.
21. Gold MR, Garan H, Ungaro MA, Buckley MJ, DeSanctis RW. Normalization of the signal-averaged electrocardiogram with coronary artery surgery. *PACE* 1992;15:547.
22. Gold MR, Buser GA, Flowers JL, Krasna MJ, Bailey RW. Laparoscopic placement of

- defibrillator patches. *European J.C.P.E.* 1992;2:A107.
23. Buser GA, Krasna MJ, Foster AH, Gold MR. A comparison of lead configurations for thoracoscopic defibrillator systems. *Circulation* 1992;86(4):I-441.
  24. Gold MR, O'Gara PT, Buckley MJ, DeSanctis RW. Predictors and prevention of the arrhythmias following coronary artery bypass surgery. *J Am Coll Cardiol* 1993;21(2):122A.
  25. Buser GA, Foster AH, Bailey RW, Flowers JL, Scott TR, Krasna MJ, Gold MR. Efficacy of thoracoscopic and laparoscopic patch placement for defibrillation. *J Am Coll Cardiol* 1993;21(2):303A.
  26. Feliciano Z, Fisher ML, Patten RD, Gottlieb SS, Gold MR. The optimal A-V delay in heart failure patients. *PACE* 1993;16(4):884.
  27. Krasna MJ, Foster AH, Laschinger JC, Buser G, Gold MR. Thoracoscopic AICD implantation: an experimental study. *Chest* 1993;103(3):162S.
  28. Feliciano Z, Fisher ML, Gottlieb SS, Gold MR. Does short A-V delay pacing improve congestive heart failure? *Circulation* 1993;88(4):I-19.
  29. Gold MR, Foster AH, Shorofsky SR. The effects of pulse width on defibrillation efficacy. *Circulation* 1993;88(4):I-157.
  30. Gold MR, Riggio DW, Feliciano Z, Shorofsky SR, Foster AH. Comparison of monophasic and biphasic waveforms for defibrillation in a nonthoracotomy lead system. *Circulation* 1993;88(4):I-215.
  31. Bustamante JO, Gold MR, Balke CW. Phosphatases required for in situ B-adrenergic and dihydropyridine agonism on L-type Ca-channel. *Circulation* 1993;88(4):I-278.
  32. Watson CL, Balke CW, Gold MR. Acute inhibition of intracellular calcium transients by amiodarone in rat ventricular myocytes. *Circulation* 1993;88(4):I-373.
  33. Watson CL, Gold MR. Modulation of cardiac  $I_{Na}$  by acidosis. *Biophysical Journal* 1994;66:A204.
  34. Foster M, Shorofsky SR, Peters RW, Gold MR. Combination therapy with type I antiarrhythmic drugs: electrophysiologic predictors of efficacy. *J Am Coll Cardiol* 1994;23:36A.
  35. Shorofsky SR, Foster AH, Gold MR. The effect of tilt on defibrillation efficacy. *J Am Coll Cardiol* 1994;23:86A.
  36. Weiss DN, Feliciano Z, Tummala RV, Shorofsky SR, Foster AH, Gold MR. Inverse relationship of defibrillation impedance and delivered energy. *J Am Coll Cardiol* 1994;23:87A.

37. Tummala RV, Riggio DW, Weiss DN, Feliciano Z, Shorofsky SR, *Gold MR*. Chronic changes in defibrillation parameters with a transvenous lead system. *J Am Coll Cardiol* 1994;23:112A.
38. Foster AH, McLaughlin JS, Fisher ML, *Gold MR*. Improved hemodynamics achieved with biventricular pacing. *J Am Coll Cardiol* 1994;23:156A.
39. Riggio DW, Peters RW, Gottlieb SS, *Gold MR*. Electrophysiologic effects of high dose oral amiodarone load in heart failure patients. *J Am Coll Cardiol* 1994;23:203A.
40. Feliciano Z, Fisher ML, Corretti MC, Gottlieb SS, *Gold MR*. Acute hemodynamic effect of A-V delay in patients with congestive heart failure. *J Am Coll Cardiol* 1994;23:349A.
41. Gottlieb SS, Lauria S, Riggio DW, Peters RW, Shorofsky SR, Cines M, Froman D, *Gold MR*. High dose oral amiodarone loading exerts important hemodynamic actions in patients with congestive heart failure. *J Am Coll Cardiol* 1994;23:384A.
42. Reese DB, Silverman ME, Brackett JC, Pressel MD, *Gold MR*, Gottlieb SS. VT length is a better predictor of mortality than frequency of VT or VPD in patients with CHF. *J Am Coll Cardiol* 1994;23:391A.
43. Weiss DN, Feliciano Z, Tummala RV, Shorofsky SR, Foster AH, *Gold MR*. Inverse relationship of defibrillation impedance and delivered energy. *Circulation* 1994;90:(4):I-177.
44. Shorofsky SR, Foster AH, *Gold MR*. The effect of polarity reversal on biphasic defibrillation threshold with an integrated transvenous lead system. *Circulation* 1994;90:(4):I-228.
45. Tummala RV, Weiss DN, Feliciano Z, Shorofsky SR, *Gold MR*. The effects of defibrillation on endocardial rate-sensing leads. *Circulation* 1994;90:(40):I-498.
46. Florin TJ, Weiss DN, Feliciano Z, Tummala RV, Shorofsky SR, Peters RW, *Gold MR*. Induction of atrial fibrillation with low energy shocks. *Circulation* 1994;90:(40):I-541.
47. Weiss DN, Tummala RV, Feliciano Z, Peters RW, Shorofsky SR, Froman DM, *Gold MR*. A comparison of d-sotalol and d,l-sotalol for treatment of ventricular tachycardia. *Circulation* 1994;90:(40):I-544.
48. Watson CL, *Gold MR*. The effects of intracellular lysophosphatidylcholine on cardiac  $I_{Na}$ . *Biophysical Journal* 1995;68:(2):A153.
49. Peters RW, McQuillan S, Kaye SA, *Gold MR*. Increased Monday incidence of life threatening ventricular arrhythmias: experience with a third generation implantable defibrillator. *J Am Coll Cardiol* 1995;25:188A.
50. Tummala RV, Khalighi K, Weiss DN, Shorofsky SR, *Gold MR*. Prolonged redetection of

- ventricular fibrillation with an integrated lead system. *J Am Coll Cardiol* 1995;25:316A.
51. Gold MR, Foster AH, Shorofsky SR. Enhanced defibrillation efficacy with an active pectoral pulse generator. *J Am Coll Cardiol* 1995;25:407A.
  52. Buxton AE, Greer GS, Gold MR, DiCarlo L, O'Toole MF, Fisher JD, Prystowsky EN, Hook BG, Bernstein RC, Hafley G, for the Multicenter Unsustained Tachycardia Trial Investigators. Can clinical characteristics predict inducible sustained ventricular tachycardia in potentially high risk patients with coronary artery disease? *Circulation* 1995;92:I-98.
  53. Florin TJ, Weiss DN, Feliciano Z, Tummala RV, Khalighi K, Schneider A, Shorofsky SR, Peters RW, Gold MR. The induction of atrial fibrillation with low energy defibrillator shocks is related to lead and pulse width. *Circulation* 1995;92:I-141.
  54. Gold MR, Foster AH, Shorofsky SR. Reduction of defibrillation thresholds with an active pectoral pulse generator and a dual coil lead. *Circulation* 1995;92:I-339.
  55. Freed LA, Eagle KA, Mahjoub ZA, Smith AJC, Gold MR, O'Gara PT, Paul SD. Gender differences in patients with unexplained syncope. *JACC* 1996;27:107A.
  56. Shorofsky SR, Kavesh NG, Gold MR. Strength-duration relation for human transvenous defibrillation. *Circulation* 1996;94:(8):I-132.
  57. Gold MR, Kavesh NG, Peters RW, Shorofsky SR. Biphasic waveforms prevent the chronic rise of transvenous defibrillation thresholds. *Circulation* 1996;94:(8):I-321.
  58. Mahjoub ZA, Eagle KA, Smith CAJ, Gold MR, O'Gara PT, Paul SD. Clinical decision making for the cost-effective evaluation of patients with unexplained syncope: role of noninvasive testing. *Circulation* 1996;94:(8):I-334.
  59. Gold MR, Khalighi K, Shorofsky SR. Predictors of the improvement of defibrillation thresholds with an active pulse generator. *Circulation* 1996;94:(8):I-440.
  60. Cain ME, Gomes JA, Hafley GE, Lee KL, Gold MR. Performance of the signal-averaged ECG in identifying patients inducible into sustained ventricular tachycardia. *Circulation* 1996;94:(8):I-451.
  61. Gold MR, Fisher ML, Gottlieb SS. Failure of short atrioventricular delay pacing to improve hemodynamic function in patients with congestive heart failure. *HeartWeb* 1996;2(2).
  62. Watson CL, Gold MR. Sodium current kinetics are modulated by  $[Ca^{2+}]_i$  and protein kinase C. *Biophysical Journal* 1997;72:(2):A363.
  63. Gold MR, Zhang X, Palmer G, Peters RW, Kavesh NG, Shorofsky SR. Clinical predictors and efficacy of antitachycardia pacing therapy for the treatment of ventricular tachycardia. *PACE* 1997;20:1567.

64. Watson CL, Gold MR. Modulation of  $I_{Na}$  inactivation by Ca via protein kinase C and tyrosine kinase. *Circulation* 1997;96:I-121.
65. Kavesh NG, Sarang SE, Gold MR. Arrhythmic risk stratification by special analysis of 192-lead signal averaged body surface maps. *Circulation* 1997;96:I-459.
66. Olsovsky MR, Kavesh NG, Pelini MA, Shorofsky SR, Gold MR. Optimization of active can defibrillation lead systems. *Circulation* 1997;96:I-579.
67. Kavesh NG, Shorofsky SR, Sarang SE, Gold MR. The effect of heart rate on T wave alternans. *Circulation* 1997;96:I-582.
68. Olsovsky MR, Pelini MA, Kavesh NG, Shorofsky SR, Gold MR. Serial changes of active can defibrillation thresholds. *Circulation* 1997;96:I-720.
69. Kavesh NG, Shorofsky SR, Sarang SE, Gold MR. The effect of procainamide on T wave alternans. *Circulation* 1997;96:I-746.
70. MM Kirk, CW Balke, Gold MR, Shorofsky SR. The effect of temperature on spontaneous calcium sparks in human atrial myocytes. *Biophysical Journal* 1998;74:A270.
71. Gold MR, Hafley GE, Dicarlo LA, Lehmann MH, Page RL, Lee KL, Buxton AE. Clinical predictors of antiarrhythmic drug response in the MUSTT trial. *JACC* 1998;31:159A.
72. Brockman RG, Olsovsky MR, Shorofsky SR, Gold MR. The acute hemodynamic effects of pacing site and mode in congestive heart failure. *JACC* 1998;31:389A.
73. Olsovsky MR, Shorofsky SR, Gold MR. Comparison of transvenous and unipolar defibrillation thresholds. *JACC* 1998;31:514A
74. Shorofsky SR, Olsovsky MR, Gold MR. Effects of second phase duration on transvenous defibrillation efficacy with biphasic waveforms. *PACE* 1998;21:847.
75. Gold MR, Kavesh NG, Anderson KP, Bloomfield DM, Estes NA M, Michaud GF, Wilber DJ, Cohen RJ, Rosenbaum DS. Correlation of T-wave alternans during exercise with the induction of ventricular tachycardia. *PACE* 1998;21:861.
76. Cooklin M, Olsovsky MR, Brockman RG, Hsu W, Shorofsky SR, Gold MR. Atrial defibrillation thresholds with ventricular defibrillator lead systems. *PACE* 1998;21:930.
77. MacMurdy KS, Shorofsky SR, Peters RW, Olsovsky MR, Gold MR. The accuracy of T wave alternans to predict the inducibility of ventricular tachycardia in patients with ischemic cardiomyopathy. *Circulation* 1998;98(17):I648.
78. Cooklin M, Olsovsky MR, Brockman RG, Shorofsky SR, Gold MR. Comparison of atrial defibrillation thresholds with ventricular defibrillator lead configurations. *Circulation* 1998;98(17):I190

79. Gold MR, Hsu W, Marcovecchio AF, Olsovsky MR, Kirk MM, Brockman RG, Shorofsky SR. A new tachyarrhythmia discrimination algorithm for implantable defibrillators. *Circulation* 1998;98(17):I191
80. Cooklin M, Shorofsky SR, Olsovsky MR, Gold MR. Predictors of atrial defibrillation threshold in patients with single lead ICDs. *Circulation* 1998;98(17):I428
81. Gold MR, Bloomfield DM, Anderson KP, Wilber DJ, El-Sherif N, Estes MM, Groh WJ, Kaufman ES, Greenberg ML, Cohen RJ. T wave alternans predicts arrhythmia vulnerability in patients undergoing electrophysiology study. *Circulation* 1998;98(17):I647.
82. Kirk MM, Cooklin M, Shorofsky SR, Gold MR. Beta adrenergic blockade decreases T wave alternans. *JACC* 1999;33(2):108A.
83. Degeratu FT, Peters RW, Shorofsky SR, Gold MR. Sensing lead failure in implantable cardioverter defibrillators. *JACC* 1999;33(2):142A.
84. Gold MR, Bloomfield DM, Anderson KP, Wilber DJ, El-Sherif N, Estes NA M, Groh WJ, Kaufman E, Cohen RJ. A comparison of T wave alternans, signal averaged electrocardiography and electrophysiology study to predict arrhythmia vulnerability. *JACC* 1999;33(2):145A.
85. Page RL, Luceri RM, Gold MR, Peters R, Follmann DA, Russo AM, Powell JL, Bigger JT, Kim CH, Sung RJ, Zipes DP, Yao Q, Lancaster S and the AVID Investigators. Patterns of mortality in the antiarrhythmics versus implantable defibrillators (AVID) study registry: evidence for increased mortality related to the winter holidays. *PACE* 1999;22(4):712.
86. Kirk MM, Shorofsky SR, Gold MR. Right sided active pectoral pulse generators do not reduce defibrillation thresholds. *PACE* 1999;22(4):747.
87. Bloomfield DM, Gold MR, Anderson KP, Kaufman ES, El-Sherif N, Estes M, Greenberg ML, Groh WJ, Wilber DR, Cohen RJ. A comparison of t wave alternans and signal-averaged electrocardiography in predicting outcome of electrophysiology testing. *PACE* 1999;22(4):751.
88. MacMurdy KS, Shorofsky SR, Olsovsky MR, Gold MR. T wave alternans predicts arrhythmia vulnerability in patients with ischemic cardiomyopathy. *PACE* 1999;22(4):767.
89. Peline MA, Olsovsky MR, Shorofsky SR, Gold MR. The effects of radiofrequency catheter ablation guided by intracardiac echocardiography on atrioventricular nodal conduction in atrial fibrillation. *PACE* 1999;22(4):820.
90. Olsovsky MR, Cooklin M, Shorofsky SR, Gold MR. A randomized comparison of active pectoral lead configurations for atrial defibrillation. *Circulation* 1999;100(18):I-152.
91. MacMurdy KS, Shorofsky SR, Olsovsky MR, Sarang SR, Gold MR. A comparison of

- twave alternans and programmed stimulation to predict spontaneous ventricular arrhythmias. *Circulation* 1999;100(18)I-309.
92. Exner DV, Lancaster SE, Pinski SL, Graham-Renfroe E, Wyse G, Coromilas J, Follmann D, Gold MR, Beckman KJ, Karagounis L, Hallstrom A. Electrical storm is an independent risk factor for early death: the antiarrhythmics versus implantable defibrillators (AVID) trial. *Circulation* 1999;100(18)I-366.
  93. Packer DL, Munger TM, Gold MR, Hafley GE. Impact of initial ischemic burden on the benefit of IDC therapy in the MUSTT trial. *Circulation* 1999;100(18)I-367.
  94. Bloomfield DM, Gold MR, Anderson KP, Wilber DJ, El-Sherif N, Estes M, Groh WJ, Kaufman ES, Greenberg ML, Rosenbaum DS, Dabbous OH, Cohen RJ. Twave alternans predicts events in patients with syncope undergoing electrophysiologic testing. *Circulation* 1999;100(18)I-508.
  95. MacMurdy KS, Kirk MM, Cooklin M, Shorofsky SR, Gold MR. The effect of selective autonomic blockade on twave alternans. *Circulation* 1999;100(18)I-509.
  96. Gold MR Hummel JD, Olsovsky MR, Giudici MC, Laskey WL, Shorofsky SR Tockman BA, Ding J, Spinelli JC. A new lead system for left ventricular pacing. *Circulation* 1999;100(18)I-515.
  97. Gold MR, Rottman JN, Wood MA, Lehmann MH, Wyse GD, Batsford WP, Peters RW, Hafley GE, Buxton AE. The effect of clinical factors on the benefit of implantable defibrillators in the MUSTT trial. *Circulation* 1999;100(18)I-642.
  98. Gold MR, Olsovsky MR, DeGroot PJ, Cuello C, Shorofsky SR. The effect of superior vena cava coil position on active can defibrillation thresholds. *PACE* 1999;22(2)A22.
  99. Gold MR, Daubert JP, Peters RW, Shorofsky SR. A clinical trial of a combined atrial and ventricular defibrillator in patients without ventricular arrhythmias. *JACC* 2000;35(2)115A.
  100. Peters RW, Gold MR, Carlson MD, Zipes DP, Follman D, Sheldon RS, Mounsey P, Lancaster S, AVID Investigators. Seasonal variation in implantable cardioverter defibrillator therapy. *JACC* 2000;35(2)150A.
  101. Gold MR, O'Toole MF, Tang A, Coromilas J, Hafley GE, Lee K, Buxton AE. The effect of ejection fraction and congestive heart failure on the benefit of implantable defibrillators in MUSTT. *PACE* 2000;23:559.
  102. Daoud E, Hummel J, Gold MR, Saxon L, Higgins S, DiCarlo L, Yong. Impact of biventricular pacing on mortality in a randomized crossover study of patients with heart failure and ventricular arrhythmias. *PACE* 2000;23:569.
  103. Bloomfield DM, Gold MR, Anderson KP, Wilber DJ, Sherif NE, Estes M, Groh WJ, Kaufman ES, Greenberg ML, Rosenbaum DS, Dabbous OH, Cohen RJ. T-wave alternans

- predicts events independent of ejection fraction and etiology of heart disease in patients undergoing electrophysiologic testing for evaluation of known or suspected ventricular arrhythmias. *PACE* 2000;23:593.
104. MacMurdy KS, Sarang S, Rashba EJ, Shorofsky SR, *Gold MR*. The influence of gender on spontaneous ventricular arrhythmias and T-wave alternans in patients with ischemic cardiomyopathy. *PACE* 2000;23:594.
  105. Rashba EJ, Olsovsky MR, Shorofsky SR, Kirk M, Cooklin M, Peters RW, *Gold MR*. Defibrillation thresholds improve significantly over time with an active pectoral lead system. *PACE* 2000;23:631.
  106. Hsu W, KenKnight BH, Lang DJ, Olsovsky MR, Shorofsky SR, *Gold MR*. Synchronizing atrial defibrillation shocks using R-wave sensing algorithms in current dual-chamber ICD's. *PACE* 2000;23:677.
  107. MacMurdy KS, Shorofsky SR, Sarang S, *Gold MR*. T-wave alternans predicts arrhythmia vulnerability in patients with ischemic cardiomyopathy undergoing electrophysiology study. *PACE* 2000;23:689.
  108. Niazi I, *Gold MR*, Hummel J, Daoud E, Higgins S, Giudici M, Worley S, DiCarlo L, Yong P. Performance characteristics of a novel steroid-eluting coronary sinus lead designed for left ventricular pacing. *PACE* 2000;23:719.
  109. *Gold MR*. Follow-up and future directions of pacemaker therapy: where are we realistically going from here? *Europace* 2000;1:D6.
  110. Nisam S, *Gold MR*. MUSTT rebuttals to MADIT objections. *Europace* 2000;1:D172.
  111. *Gold MR*, Rashba EJ, Kroll MW, Shorofsky SR. *Europace* 2000;1:D271.
  112. Buxton AE, Prystowsky EN, Hafley GE, Josephson ME, Fisher JD, *Gold MR*, Batsford W, McGinnis D, Radler E, Lee KL. Characteristics of nonsustained ventricular tachycardia in the multicenter unsustained tachycardia trial (MUSTT) permit programming defibrillators to avoid unnecessary discharges. *PACE* 24 (II) 2001;122.
  113. *Gold MR*, Higgins S, Klein R, Gilliam FR, Hahn S, Breiter D, Peterson-Nordby K. Is a defibrillation energy margin greater than 10 joules necessary?: primary endpoint data from the low energy safety study (LESS). *PACE* 24 (II) 2001;153.
  114. *Gold MR*, Kim J, Bocek J, Hus W, Wagner D, DiCarlo L, Rashba EJ, Shorofsky SR. Rhythm discrimination using a new electrogram (EGM) vector timing and correlation (VTC) algorithm. *PACE* 24 (II) 2001;155.
  115. Gilliam FR, *Gold MR*, Higgins S, Klein R, Simones M, Peterson-Nordby K, Hahn S. Induced VF conversion testing predicts successful conversion of spontaneous VF: results from the low energy safety study (LESS). *PACE* 24 (II) 2001;290.

116. Klein R, McClelland J, Gold MR, Higgins S, Rodenhiser K, Breiter D. Does induction method affect defibrillation thresholds in patients with an implantable cardioverter defibrillator (ICD). *PACE* 24 (II) 2001;401.
117. Osman AF, Rashba EJ, Shorofsky SR, Gold MR. Prognostic value of voltage magnitude during t wave alternans (TWA) assessment with exercise and pacing in patients with ischemic cardiomyopathy. *PACE* 24 (II) 2001;530.
118. Gold MR, Higgins S, Klein R, Gilliam FR, Peterson-Nordby K, Breiter D, Hahn S. Temporal changes of implantable defibrillator efficacy: primary endpoint analysis for the low energy safety study (LESS). *PACE* 24 (II) 2001;595.
119. Davoudi R, Swygman CA, Saeed M, Gold MR, Higgins S, Link MS, Homoud MK, Nunley S, Estes NAM, Wang PJ. Is there an atrial vulnerable period for induction of atrial fibrillation by sinus test shocks? *PACE* 24 (II) 2001;732.
120. Gold MR. T-wave alternans for arrhythmia risk stratification. *The Journal of Heart Disease* 2001;2(1)107.
121. Kirby SR, Degeratu FT, Rashba EJ, Shorofsky SR, Peters RW, Gold MR. The efficacy of multimodal therapy with pacing, cardioversion and amiodarone to maintain sinus rhythm in patients with "chronic" atrial fibrillation and congestive heart failure. *J Am Coll Cardiol* 2001;37(2)(Supplement A) 93A.
122. Murphy L, Bouhouch R, Rashba EJ, Shorofsky SR, Gold MR. Clinical predictors of atrial defibrillation thresholds with a dual coil active can lead system. *J Am Coll Cardiol* 2001;37(2)(Supplement A) 96A.
123. Bouhouch R, Rashba EJ, Joy RA, Kirby SR, Shorofsky SR, Osman AF, Gold MR. A prospective randomized comparison of transvenous and active can atrial defibrillation thresholds. *J Am Coll Cardiol* 2001;37(2)(Supplement A) 100A.
124. Shorofsky SR, Rashba EJ, Gold MR. Comparison of step-down and binary-search algorithms for determination of defibrillation thresholds in humans. *J Am Coll Cardiol* 2001;37(2)(Supplement A) 137A.
125. Gold MR, Sulke N, Schwartzman D, Johnson LJ, Mehra R, Euler DE. Evaluation of atrial defibrillation and pacing for atrial arrhythmias. *Europace* 2001;125-129.
126. Gold MR, Brown S, Johnson L, Sulke D for the Jewel AF-Only Investigators. Evaluation of atrial defibrillation and pacing for atrial arrhythmias. *Europace* 2001;2:B50.
127. Gold MR, Brown S, Johnson L, Santini M for the Jewel AF-Only Investigators. Spontaneous ventricular arrhythmias in patients with atrial fibrillation. *Europace* 2001;2:B105.
128. Carlson MD, Gold MR, Ip J, Messenger J, Beau S, Cameron D, The ADOPT Investigators. Dynamic atrial overdrive pacing decreases symptomatic atrial arrhythmia burden in

- patients with sinus node dysfunction. *Circulation* 2001;104:1825.
129. Hamzei AR, Gold MR, Kerwin W, Peter CT, Cates A, Chen PS, Karagueuzian HS. Entropy-based differentiation of ventricular tachycardia from atrial fibrillation using intracardiac electrograms. *Circulation* 2001;104:2674.
  130. Shorofsky SR, Rashba EJ, Gold MR. Biphasic waveforms do not improve defibrillation efficacy by altering the strength-duration relation of the first phase. *Circulation* 2001;104:2675.
  131. Klein RC, Gold MR, Higgins S, Gilliam R, Hahn S. The low energy safety study: baseline characteristics and results of defibrillation testing. *Circulation* 2001;104:3091.
  132. Osman AF, Rashba EJ, Shorofsky SR, Gold MR. Atrial pacing is superior to exercise for t wave alternans measurement. *Circulation* 2001;104:3257.
  133. Rashba EJ, Macmurdy K, Cooklin M, Kirk M, Peters RW, Shorofsky SR, Gold MR. Sympathetic blockade markedly reduces t wave alternans. *Circulation* 2001;104:3258.
  134. Osman AF, Rashba EJ, Shorofsky SR, Gold MR. Effect of QRS duration on the diagnostic performance of t wave alternans. *Circulation* 2001;104:3259.
  135. Gold MR, Higgins S, Klein R, Gilliam R, Simones M, Breiter D, Hahn S. The effect of programmed energy safety margins on defibrillator efficacy: primary endpoint analysis from the low energy safety study (LESS). *Circulation* 2001;104:3636.
  136. Rashba EJ, Osman A, MacMurdy K, Sarang S, Shorofsky SR, Gold MR. Exercise is superior to pacing for T wave alternans measurement. *J Am Coll Cardiol* 2002; 39(5)(Supplement A) 80A.
  137. Gold MR, Shorofsky SR, Rashba EJ. Is one successful VF conversion adequate for safe ICD implanantion? *J Am Coll Cardiol* 2002; 39(5)(Supplement A) 87A.
  138. Markwood TT, Joy R, Rashba EJ, Shorofsky SR, Gold MR. Are programmable shock vectors required to optimize atrial defibrillation? *J Am Coll Cardiol* 2002; 39(5)(Supplement A) 93A.
  139. Murphy LA, Rashba EJ, Shorofsky SR, MacMurdy K, Gold MR. Female gender is associated with a decreased prevalence of T wave alternans. *J Am Coll Cardiol* 2002; 39(5)(Supplement A) 95A.
  140. Klein R, Higgins S, Gold MR, Gilliam R, Breiter D, Hahn S. The low energy safety study: baseline characteristics and results of defibrillation testing. *Europace Supplements* 2002;3:A169.
  141. Klein R, Gold MR, Higgins S, Gilliam R, Breiter D, Hahn S. ICD energy safety margins: induced VF data from the low energy safety study (LESS). *Europace Supplements* 2002;3:A251.

142. Gold MR, Gilliam R, Higgins S, Klein R, Breiter D, Hahn S. Induced VF testing predicts successful conversion of spontaneous VF: results of the low energy safety study (LESS). *Europace Supplements* 2002;3:A97.
143. Gold MR, Breiter D, Hahn SJ, Rashba EJ, Shorofsky SR. The safety of one successful VF conversion for ICD implantation. *Europace Supplements* 2002;3:A98.
144. Gold MR, Kim J, Bocek J, Hsu W, Wagner D, Dicarolo L, Rashba EJ, Shorofsky SR. Advanced rhythm discrimination using electrogram vector timing and correlation for implantable cardioverter defibrillators. *Europace Supplements* 2002;3:A254.
145. Gold MR, Hue-The S, Herre J, Breiter D, Zhang Y, Schwartz M. Spontaneous conversion efficacy and defibrillation threshold: comparison of right and left-sided pectoral active can defibrillator patients. *Supplement to Circulation* 2002;106;19:1616.
146. Gold MR, Freedman R, Breiter D, Zhang Y, Schwartz M. The impact of dual-versus single-chamber implantable cardioverter-defibrillator implantation on survival. *JACC* 2003;41:138A.
147. Gold MR, Newman D, Schaaf K, Johnson L. Atrial defibrillation and health-related quality of life (QOL). *PACE* 2003;26:338.
148. Gold MR, Mukherjee R, Lowry AS, Allen RA, Stroud MR, Wharton JM, Ikonomidis JS, Crumbley AJ, Spinale FG. Selective induction of matrix metalloproteinases and tissue inhibitor of matrix metalloproteinase in atrial myocardium in patients with atrial fibrillation. *Circulation* 2003;108:450.
149. Shorofsky SR, Swerdlow CD, Havel WJ, Belk PA, DeGroot PJ, Gold MR, Rashba EJ. Improved defibrillation efficacy in humans with an ascending ramp waveform. *Circulation* 2003;108:1529.
150. Crawford FA, Killip D, Franklin J, Spencer WH, Gold MR. Implantable cardioverter-defibrillators for primary prevention of sudden cardiac death in patients with hypertrophic obstructive cardiomyopathy after alcohol septal ablation. *Circulation* 2003;108:1791.
151. Mukherjee R, Lowry AS, Hardin AE, Stroud MR, Ikonomidis JS, Wharton JM, Spinale FG, Gold MR. Myocardial and plasma levels of matrix metalloproteinase-9 are increased with atrial fibrillation. *JACC* 2004;43:106A.
152. Buxton AE, Lee KL, Hafley GE, Prystowsky EN, Josephson ME, Fisher JD, Gold MR. A simple model using the MUSTT database can stratify total mortality and sudden death risk of coronary disease patients. *JACC* 2004;43:425A.
153. Simon RD, Sturdivant L, Leman R, Wharton JM, Gold MR. The role of dofetilide to reduce defibrillation thresholds in patients with an inadequate defibrillation safety margin. *Heart Rhythm* 2004;1:S42(128).

154. Gold MR, Fain E, Ip J, Messenger J, Bean S, Kalbfleisch S. Frequent ventricular pacing attenuates the benefit of dynamic atrial overdrive for the prevention atrial fibrillation. *Heart Rhythm* 2004;1:S65(201).
155. Gold MR, Fain E, Ip J, Messenger J, Beau S, Kalbfleisch S. Ventricular pacing on prevention of symptomatic atrial fibrillation. *Europace Supplements* 2004;6:126(170/1).
156. Gold MR, Freedman R, Gilliam FR, Schwartz M, Zhang Y, Breiter D. Predictors of mortality in patients with implantable defibrillators. *Europace Supplements* 2004;6:143(180P/2).
157. Sturdivant JL, Leman RB, Simon RB, Wharton JM, Yu Y, Ding J, Daum D, Gold MR. Biventricular pacing improves right ventricular but not left ventricular function in patients with right bundle branch block. *Circulation Supplement III* 2004;110:17:3357.
158. Mukherjee R, Herron AR, Stroud RE, Stroud MR, Ikonomidis JS, Crumbley AJ, Frankis MB, Wharton JM, Gold MR. Selective and chamber-specific induction of matrix metalloproteinases and matrix remodeling in myocardium of patients with atrial fibrillation. *Circulation Supplement III* 2004;110:17:3100.
159. Simon RD, Sturdivant JL, Leman R, Wharton JM, Gold MR. Dofetilide significantly reduces defibrillation thresholds in patients with an inadequate defibrillation safety margin. *Circulation Supplement III* 2004;110:17:3245.
160. Simon RDB, Burke S, Sturdivant L, Leman R, Gold MR, Knick B, Wharton JM. Does increased area of pulmonary vein isolation decrease the number of non pulmonary initiators of atrial fibrillation? *JACC* 2005;45:3:124A.
161. Burke SW, Crawford FA III, Spencer WH III, Nielsen C, Simon RDB, Sturdivant JL, Wharton JM, Leman RB, Gold MR. Markers of arrhythmia vulnerability do not predict defibrillator shocks in patients with hypertrophic obstructive cardiomyopathy. *JACC* 2005;45:3:107A.
162. Gold MR, Leman R, Niazi I, Giudici M, Kim M, Yu Y, Arcot-Krishnamurthy S, Strakna J. Is nominal AV delay offset optimal for heart failure patients receiving cardiac resynchronization therapy? *Europace Supplements* 2005;7:168(748).
163. Gold MR, Niazi I, Giudici M, Leman R, Kim M, Yu Y, Arcot-Krishnamurthy S, Strakna J. A new automated algorithm for optimizing AV delay to improve global LV contractile function with cardiac resynchronization therapy. *Europace Supplements* 2005;7:213(877).
164. Niazi I, Gold MR, Giudici M, Kim M, Leman R, Yu Y, Arcot-Krishnamurthy S, Newman M, Hoyhtya A. Acute hemodynamic effect of overdrive atrial pacing during cardiac resynchronization therapy. *Heart Rhythm* 2005;2;1S:AB39-4.
165. Sturdivant JL, Leman RB, Simon RB, Wharton JM, Yu Y, Ding J, Arcot-Krishnamurthy S, Strakna J, Gold MR. Comparison of acute hemodynamic effects of cardiac resynchronization therapy in patients with right and left bundle branch block. *Heart*

*Rhythm* 2005;2;1S:P1-78.

166. Gold MR, Higgins S, Daoud EG, Li D, Merz D, Schwartz M, Zhang Y, Giudici M. Comparison of complication-free rate between ICD and CRT-D trials. *Heart Rhythm* 2005;2;1S:P3-92.
167. Simon RB, Burke SW, Sturdivant JL, Leman RB, Gold MR, Wharton JM. Comparison of efficacy of three different atrial fibrillation ablation methods. *Heart Rhythm* 2005;2;1S:P4-64.
168. Giudici M, Gold MR, Niazi IK, Leman RB, Kim M, Kalbfleisch J, Yu Y, Arcot-Krishnamurthy S, Schrumph P, Ding J. A new AV delay optimization algorithm increases LV global contractile function in CRT patients compared with echo derived methods of AV delay programming. *Heart Rhythm* 2005;2;1S:P4-106.
169. Burke SW, Crawford FA, Spencer WH, Nielsen CD, Simon RB, Sturdivant JL, Wharton JM, Leman RB, Gold MR. Traditional risk factors for sudden cardiac death do not predict defibrillator shocks in patients with hypertrophic obstructive cardiomyopathy following alcohol septal ablation. *Heart Rhythm* 2005;2;1S:P5-91.
170. Gold MR, Niazi IK, Giudici M, Leman RB, Kim M, Yu Y, Arcot-Krishnamurthy S, Strakna J, Ding J. A new automated algorithm for optimizing AV delay to improve global LV contractile function with cardiac resynchronization therapy. *Heart Rhythm* 2005;2;1S:P5-104.
171. Simon RB, Burke SW, Sturdivant JL, Leman RB, Gold MR, Wharton JM. Predictors of non-pulmonary initiators in patients undergoing atrial fibrillation ablation. *Heart Rhythm* 2005;2;1S:P6-60.
172. Gold MR, Shih, HT, Herre J, Schwartz M, Zhang Y, Breiter D. Mortality differences among patients with right and left sided defibrillator implants. *Circulation* 2005;112:17:1844.
173. Colley BJ, Maran A, Nappi J, Sturdivant JL, Leman RB, Wharton JM, Gold MR. A comparison of bleeding complications associated with warfarin and coumadin among patients undergoing device implantation. *JACC* 2006;47(4) Supplement A:969-137:23A.
174. Gold MR, Mollerus M, DeLurgio D, Strakna J, Fleming L, Cumming C. Effect of different cardiac resynchronization therapy pacing modalities on ventricular tachycardia/ventricular fibrillation events in heart failure patients. *JACC* 2006;47(4) Supplement A:947-125:14A.
175. Sayar SN, Sturdivant JL, Burke S, Leman RB, Wharton JM, Yarborough J, Gold MR. Utility of electronic reprogrammable vectors in biventricular devices. *JACC* 2006;47(4) Supplement A:947-134:16A.
176. Burke SW, Spencer WH, Sturdivant JL, Leman R, Nielsen CD, Wharton JM, Gold MR. Defibrillation thresholds in patients with hypertrophic cardiomyopathy. *JACC* 2006;47(4) Supplement A:947-133:16A.

177. Pereira N, Levy SM, Sethuramen B, Nelson-Twakor O, *Gold MR*. Baseline systolic blood pressure predicts response to cardiac resynchronization therapy in heart failure patients. *JACC* 2006;47(4) Supplement A:969-142:24A.
178. Colley BJ, Maran A, Nappi JM, *Gold MR*, Sturdivant LJ, Wharton JM, Leman RB. A comparison of bleeding complications associated with warfarin and heparin among patients undergoing device implantation. Supplement to *Heart Rhythm* 2006;3;1S:AB6-1.
179. Burke SW, Spencer WH, LJ Sturdivant, Leman RB, Nielsen CD, Wharton JM, *Gold MR*. Defibrillation thresholds in patients with hypertrophic cardiomyopathy. Supplement to *Heart Rhythm* 2006;3;1S:AB26-3.
180. Burke SW, Spencer WH, Nielsen CD, Ben Simon RD, Sturdivant LJ, Leman RB, Wharton JM, *Gold MR*. Development of right bundle branch block after alcohol septal ablation for hypertrophic obstructive cardiomyopathy is associated with a prolonged HV interval. Supplement to *Heart Rhythm* 2006;3;1S:P1-34.
181. Patton KK, Poole JE, *Gold MR*, Wang T, Johnson GW, Hellkamp AS, Anderson J, Callans DJ, Raitt MH, Reddy RK, Marchlinski FE, Yee R, Guarnieri T, Wilber DJ, Talajic M, Mark DB, Lee, KL, Bardy GH and the SCD-HeFT Investigators. Septadian variation in life-threatening ventricular arrhythmias in SCD-HEFT. Supplement to *Heart Rhythm* 2006;3;1S:P2-69.
182. Patton KK, Poole JE, *Gold MR*, Wang T, Johnson GW, Hellkamp AS, Anderson J, Callans DJ, Raitt MH, Reddy RK, Marchlinski FE, Yee R, Guarnieri T, Wilber DJ, Talajic M, Mark DB, Lee, KL, Bardy GH and the SCD-HeFT Investigators. Circadian variation of ventricular arrhythmias in SCD-HEFT. Supplement to *Heart Rhythm* 2006;3;1S:P2-78.
183. Burke SW, Sturdivant LJ, Leman RB, Wharton JM, *Gold MR*. Defibrillation thresholds in patients with cardiac resynchronization therapy defibrillators. Supplement to *Heart Rhythm* 2006;3;1S:P2-81.
184. Sturdivant LJ, Niazi IK, Krishnamurthy SA, Strakna J, Waggoner AD, *Gold MR*. Prospective comparison of AV optimization methods for cardiac resynchronization therapy in atrial sensed and paced modes. Supplement to *Heart Rhythm* 2006;3;1S:P4-94.
185. Bunting TA, Usher B, Chiaramida S, Taylor M, Leman RB, Wharton JM, *Gold MR*. Transesophageal echocardiogram screening is indicated in patients with atrial fibrillation undergoing evaluation for ventricular arrhythmias. Supplement to *Heart Rhythm* 2006;3;1S:P5-43.
186. *Gold MR*, Higgins S, Daoud E, Li D, Schwartz M, Zhang Y, Giudici M. Complications of implantable cardioverter defibrillators: single chamber vs. dual chamber vs. cardiac resynchronization devices. *Europace Supplements* 2006;8:Supplement 1:104/6.
187. Prakash A, *Gold MR*, Haffajee C, Munneke D, Zhou D. Impact of atrial pacing on AF burden: insights from the SAFARI study. *Europace Supplements* 2006;8:Supplement

1:167/2.

188. Gold MR, Niazi I, Giudici M, Leman R, Yu Y, Arcot-Krishnamurthy S, Strakna J. A new electrogram-based AV delay optimization algorithm and its comparison to traditional echo-based methods. *Europace Supplements* 2006;8:Supplement 1:186/2.
189. Gold MR, Sturdivant JL, Leman RB, Maskara B, Yu Y. Prospective validation of electrical dyssynchrony to predict the acute hemodynamic response to cardiac resynchronization therapy. *Journal of Cardiac Failure* 2006;12:150.
190. Mukherjee R, Bonnema DD, Stroud RE, Stroud MR, Spinale FG, Gold MR. Aldosterone receptor blockade does not reduce atrial collagen levels with atrial fibrillation. *Circulation* 2006;114:18:1117.
191. Gold MR, Ensley D, Chilson D, Ip JH, Constantini O, Bloomfield D, Poole J, McNulty S, Lee, K, Bardy G. T-wave alternans SCD HeFT study: primary endpoint analysis. *Circulation* 2006;114:18:2113.
192. Gold MR, Val-Mejias J, Leman RB, Tummala R, Goyal S, Kluger J, Kroll MW, Oza A. Effect of SVC coil usage and SVC electrode spacing on defibrillation thresholds. *Circulation* 2006;114:18:3256.
193. Gold MR, Niazi I, Giudici M, Leman R, Yu Y, Arcot-Krishnamurthy S, Ding J. A comparison of a new electrogram based optimization algorithm with echo derived methods of AV delay programming. *Europace Supplements* 2007;9:194.
194. Gold MR, Niazi I, Giudici M, Yu Y, Arcot-Krishnamurthy S. The effects of QRS duration and atrial pacing on atrioventricular optimization of cardiac resynchronization therapy. *JACC* 2007;49:9:2A.
195. Sturdivant JL, Leman RB, Wharton JM, Yu Y, Ding J, Arcot-Krishnamurthy S, Gold MR. Comparison of baseline dyssynchrony and acute hemodynamic effects of CRT in patients with right and left bundle branch block. *JACC* 2007;49:9:26A.
196. Colley BJ, Maran A, Funcke F, Cuoco FA, Sturdivant JL, Leman R, Wharton M, Gold MR. Defibrillation thresholds and safety profiles with cardiac resynchronization therapy devices are similar to standard implantable cardiac defibrillators. *JACC* 2007;49:9:34A.
197. Cuoco FA, Colley BJ, Spencer WH, Burke SW, Sayar SN, Kusmirek SL, Nielsen CD, Sturdivant JL, Leman RB, Wharton JM, Gold MR. Shock-free survival in patients with hypertrophic obstructive cardiomyopathy and implantable defibrillators following alcohol septal ablation. *JACC* 2007;49:9:40A.
198. Cuoco, FA, Colley J, Spencer WH, Burke SW, Sayar SN, Kusmirek SL, Nielsen CD, Sturdivant JL, Leman RB, Wharton JM, Gold MR. Microvolt T-wave alternans does not predict appropriate implantable defibrillator discharges or correlate with traditional risk factors for sudden cardiac death in patients with hypertrophic obstructive cardiomyopathy. *JACC* 2007;49:9:30A.

199. Cuoco FA, Colley BJ, Kusmirek SL, Sayar SN, Knick BJ, Lawhon BA, Walling JR, Sturdivant JL, Leman RB, *Gold MR*. Electrophysiologic properties of pulmonary vein extrasystoles in paroxysmal and persistent atrial fibrillation. *Heart Rhythm* 2007;4:5S:S16.
200. Maran A, Colley BJ, Funke E, Sturdivant JL, Leman RB, *Gold MR*. The incidence and clinical predictors of high defibrillation thresholds in CRT-D devices. *Heart Rhythm* 2007;4:5S:S86.
201. Prakash A, *Gold MR*, Haffajee CI, Manda B, Li S. Impact of atrial pacing on AF burden: long term analysis from the SAFARI study. *Heart Rhythm* 2007;4:5S:S131.
202. Colley BJ, Maran A, Cuoco FA, Funke F, Sayar SN, Kusmirek SL, Sturdivant JL, Leman RB, Wharton JM, *Gold MR*. Racial disparity in defibrillation thresholds. *Heart Rhythm* 2007;4:5S:S222.
203. Kusmirek SL, Sayar SN, Cuoco FA, Colley BJ, Lawhon BA, Knick BJ, Sturdivant JL, Leman RB, *Gold MR*, Wharton JM. Hypocalcemia after radiofrequency ablation of atrial fibrillation. *Heart Rhythm* 2007;4:5S:S336.
204. Linde C, *Gold MR*, Abraham WT, Daubert JC. CRT in patients with asymptomatic and mildly symptomatic heart failure: baseline characteristics of the resynchronization reverses remodeling in systolic left ventricular dysfunction (reverse) study population. *Circulation* 2007;116:16:II-407.
205. *Gold MR*, Leman RB, Wharton JM, Quigley JF, Sturdivant JL. A prospective randomized comparison of defibrillation thresholds from the right ventricular apex and outflow tract. *JACC* 2008;51:10:A29.
206. Cuocco F, Fernandes V, Nielsen CD, Sturdivant JL, Leman RB, Wharton JM, Spencer WH, *Gold MR*. Comparison of microvolt T-wave alternans with invasive and non-invasive risk stratifiers for sudden cardiac death in hypertrophic cardiomyopathy. *JACC* 2008;51:10:A31.
207. Greer S, Lowy J, Saeed M, Schutzman JL, Bazaz R, Searingen A, Dong Y, Hayes KN, *Gold MR*. Evoked response characteristics from different defibrillation leads for capture verification in ICD/CRT-D. *Heart Rhythm* 2008;5:5S:S-134.
208. Ellenbogen KA, Bazaz R, Sadowick BC, Saeed M, Ackerman SJ, Chisner MB, Schrumpp PE, Dong Y, Hayes KN, *Gold MR*. Capture detection performance of a right ventricular automatic threshold algorithm for ICD/CRT-D. *Heart Rhythm* 2008;5:5S:S-180.
209. Cuoco FA, Leslie DL, Luff M, Maran A, Klein MH, Forcina MS, Leman RB, Sturdivant JL, Wharton JM, *Gold MR*. Elevated defibrillation thresholds in CRT-D & ICD patients: comparisons & predictors. *Heart Rhythm* 2008;5:5S:S-237.
210. Cuoco FA, Krauthammer YS, Luff M, Leslie DL, Leman RB, Sturdivant JL, Wharton JM, *Gold MR*. The incidence and clinical predictors of Fidelis lead failures. *Heart Rhythm* 2008;5:5S:S-242.

211. Maran A, Cuoco F, Funke F, Sturdivant JL, Leman RB, Wharton JM, *Gold MR*. Impact of renal function on ventricular defibrillation thresholds. *Heart Rhythm* 2008;5:5S:S-387.
212. Hummel J, Margolis D, *Gold MR*, Kidwell G, Curran C, Brunner K, Hoyhtya A. Resolution of extracardiac stimulation with the acuity spiral lead. *Europace Supplements* 2008;10:(1) i27.
213. Greer S, *Gold MR*, Ellenbogen K, Sadowick B, Swearingen A, Huebert V, Dong Y, Hayes K, Giudici M. RV coil to can evoked response with different pocket locations for capture verification in ICD/CRT-D. *Europace Supplements* 2008;10:(1) i53.
214. Greer S, Lowy J, Saeed M, Schutzman J, Bazaz R, Swearingen A, Dong Y, Hayes K, *Gold MR*. Evaluation of evoked responses from different defibrillation leads for capture verification in ICD/CRT-D. *Europace Supplements* 2008;10:(1) i93.
215. *Gold MR*, Goel S, Turk K, Hoyhtya A, Seim G. Evaluation of COGNIS/TELIGEN sensing platform. *Europace Supplements* 2008;10:(1) i92.
216. *Gold MR*, Greer S, Haffajee C, Giudici M, Lowy J, Strakna J, Dong Y, Hayes K, Ellenbogen K. Clinical evaluation of a new right ventricular auto threshold algorithm in ICD/CRT-D. *Europace Supplements* 2008;10:(1) i92.
217. Ellenbogen K, Bazaz R, Sadowick B, Saeed M, Ackerman S, Chisner M, Schrumpp P, Dong Y, Hayes K, *Gold MR*. Evaluation of the capture detection performance of a right ventricular automatic threshold algorithm for ICD/CRT-D. *Europace Supplements* 2008;10:(1) i163.
218. Ghio S, Sutton MSJ, Tavazzi L, Plappert T, Daubert JC, Abraham WT, *Gold MR*, Linde C. CRT in mild heart failure: left ventricular remodeling in relation to heart failure etiology. Results from the resynchronization reverses remodeling in systolic left ventricular dysfunction (REVERSE) study. *Circulation* 2008;118:18(2)4346.
219. Sutton MSJ, Ghio S, Plappert T, Tavazzi L, Daubert JC, Abraham WT, *Gold MR*, Linde C. Changes in left ventricular structure and function over 12 months in patients with mild or asymptomatic heart failure with previous symptoms in the resynchronization reverses remodeling in systolic left ventricular dysfunction (REVERSE) study. *Circulation* 2008;118:18(2)4852.
220. Forcina MS, Luff M, Amin A, Cuoco FA, Klein MH, Lawhon BA, Knick BJ, Sturdivant JL, Leman RB, *Gold MR*, Wharton JM. Predictors of hypocalcemia after wide area circumferential ablation of atrial fibrillation. *Circulation* 2008;118:18(2)5686.
221. Forcina M, Klein M, Quin EM, Lawhon B, Knick B, Sturdivant JL, Leman RB, *Gold MR*, Guidry OF, Abernathy JH, Wharton JM. Effect of general anesthesia and conscious sedation on arrhythmogenic targets during atrial fibrillation ablation. *JACC* 2009;53:10:A112.
222. Sturdivant JL, Yu Y, Leman RB, *Gold MR*. Right ventricular pacing improves the right ventricular hemodynamic response in heart failure with RBBB. *JACC* 2009;53:10:A125.

223. Rajendra A, Forcina M, Klein M, Quin EM, Sturdivant JL, Leman RB, Wharton JM, Fernandes VL, Nielsen CD, Spencer WH, *Gold MR*. Electrophysiology studies for conduction system disease following alcohol septal ablation. *JACC* 2009;53:10:A126.
224. Quin EM, Tuten T, Forcina M, Klein M, Maran A, Sturdivant JL, Leman RB, Wharton JM, *Gold MR*. Defibrillation thresholds in hypertrophic cardiomyopathy. *JACC* 2009;53:10:A135.
225. Linde C, Daubert C, Abraham WT, *Gold MR*, Hassager C, Herre JM, Ghio S, Sutton M SJ, Derumeaux G. The influence of left ventricular ejection fraction on the extent of reverse remodeling by cardiac resynchronization therapy in mild heart failure: results from the resynchronization reverses remodeling in systolic left ventricular dysfunction (REVERSE) study. *JACC* 2009;53:10:A183.
226. Sutton MGSJ, Ghio S, Plappert T, Tavazzi L, Scelsi L, Daubert C, Abraham WT, *Gold MR*, Hassager C, Herre JM, Derumeaux G, Linde C. Cardiac resynchronization therapy induces major structural and functional reverse remodeling in mild heart failure. Results from the resynchronization reverses remodeling in systolic left ventricular dysfunction (REVERSE) trial. *JACC* 2009;53:10:A187.
227. Linde C, Leman R, Daubert C, Abraham WT, *Gold MR*. Cardiac resynchronization therapy in mild heart failure: is there a difference in outcome between NYHA class I versus II: results from the resynchronization reverses remodeling in systolic left ventricular dysfunction (REVERSE) trial. *JACC* 2009;53:10:A188.
228. Sutton MGST, Ghio S, Plappert T, Tavazzi L, Scelsi L, Daubert C, Abraham WT, *Gold MR*, Hassager C, Herre JM, Derumeau G, Linde C. Effects of reverse remodeling with cardiac resynchronization therapy in mild heart failure on left ventricular volume and shape: results from the resynchronization reverses remodeling in systolic left ventricular dysfunction (REVERSE) trial. *JACC* 2009;53:10:A192.
229. *Gold MR*, Linde C, Lozano IF, Daubert C, Abraham WT. Relationship of QRS duration to reverse remodeling with cardiac resynchronization therapy in mild heart failure: results from the resynchronization reverses remodeling in systolic left ventricular dysfunction (REVERSE) trial. *JACC* 2009;53:10:A135.

#### Book Reviews

1. Implantable cardioverter defibrillator therapy: the engineering-clinical interface. *PACE* 1998;21;141-142.

#### Editorial Commentary

1. Myocardial contractile reserve as a predictor of cardiac resynchronization therapy response. *Heart Rhythm Society* 2006;3;414-415.